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ABSTRACT 
 
REGULATION OF P-GLYCOPROTEIN AND ABCP 
TRANSPORTERS 
 
Dhanashri R. Kolwankar 
 
 
 The placenta plays an important role in modulating xenobiotic passage from 
mother to fetus.  Smoking is known to induce cytochrome P450 1A1 (CYP1A1) 
expression in the placenta, however its effect on P-glycoprotein (P-gp) and ABC 
transporter in placenta (ABCP) levels in placenta is not known.  In-vitro studies in 
hepatocytes have reported induction of P-gp mRNA by some polycyclic aromatic 
hydrocarbons.  To examine whether smoking can affect placental P-gp and ABCP, their 
expression and activity were determined in placentas from smokers and non-smokers.  
Uptake of [3H]-vinblastine and [3H]-mitoxantrone was used to measure P-gp and ABCP 
function, respectively and CYP1A1 activity (positive control) was assessed using 
ethoxyresorufin O-deethylation as the model reaction.  P-gp and ABCP expression was 
measured by immunoblotting.  Uptake of [3H]-vinblastine in vesicles was osmotically 
sensitive, suggesting intravesicular accumulation and was inhibited by verapamil, a P-gp 
inhibitor.  Uptake of [3H]-mitoxantrone was inhibited by fumitremorgin C, an ABCP 
inhibitor but not by verapamil.  Though CYP1A1 activity was significantly higher in 
smokers, no statistical difference (P > 0.05) was noted in P-gp and ABCP function or 
expression between smokers and non-smokers suggesting that smoking has no effect on 
placental P-gp and ABCP activity or expression.   
 In order to study the induction of P-gp, we used LS174T cells to screen for 
compounds for their ability to induce P-gp.  As CYP3A4 and P-gp are coordinately 
upregulated, CYP3A activity was also assessed as the formation of 1’-hydroxy 
midazolam.  Uptake of VBL was used to measure P-gp function and expression was 
measured by immunochemical methods.  CYP3A activity was 4 times higher and P-gp 
activity was significantly higher after rifampin treatment.  Rifampin treatment also 
produced an increase in protein abundance and surface expression of P-gp.  To assess 
involvement of the Pregnane X Receptor (PXR) in P-gp induction, a set of multiple 
compounds with varying degrees of PXR activation were evaluated for effect on P-gp 
expression.  PXR activation and P-gp expression were positively correlated, supporting 
the role of PXR in regulation of P-gp.  These data suggest that LS174T cells have the 
potential to be used in studying the effect of inducers on CYP3A and P-gp 
simultaneously.   
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CHAPTER – I 
1. LITERATURE REVIEW 
 1
  The placenta provides a link between mother and fetus, playing a critical 
role in the provision of nutrition and growth factors that are necessary for the 
development of the fetus.  The placenta also plays a protective function by serving as 
a barrier against many xenobiotics reaching the fetus.  Generally, it is preferred that 
the fetus not be exposed to xenobiotics; however, in certain cases the transfer of drugs 
to the fetus may be desired to achieve a positive therapeutic outcome.  The placenta 
also possesses drug metabolizing enzymes (DME) that can assist in metabolizing 
drugs ingested by the mother and thus are prevented from entering the fetus.  In 
addition to DMEs, it has also been demonstrated that efflux transporters are present in 
the placenta that can transport xenobiotics back to the mother and prevent fetal 
toxicity.   
 
1.1. Efflux Transporters 
  The ATP- Binding Cassette (ABC) transporter superfamily represents the 
ABC genes which encode for transmembrane proteins.  These proteins utilize ATP as 
the energy source to carry out efflux of xenobiotics and are termed as ABC 
transporters.  These ABC transporters have ATP binding domains and transmembrane 
domains and depending on the number of domains, they are divided as full or half 
transporters.  So far, 48 ABC genes belonging to this ABC superfamily have been 
identified and the Human Genome Nomenclature Committee has developed a 
nomenclature system for the genes belonging to this superfamily.  These genes have 
been classified into seven subfamilies, ABCA – ABCG, based on their sequence 
homology in ATP binding domains and transmembrane domains, similarities in gene 
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structure and order of domains [1].  Table 1.1 lists the subfamilies and number of 
genes belonging to each subfamily.  The members within each subfamily are then 
assigned an arabic number as a suffix.  Out of the 48 transporters, 2 transporters 
studied by us are discussed in this manuscript and are listed in Table 1.2.  The 
currently accepted nomenclature will be used throughout for consistency.  An 
extensive list of 48 transporters can be found at 
http://nutrigene.4t.com/humanabc.htm 
 
 
Table 1-1  Division of ABC superfamily of transporters into seven subfamilies  
Name ABC1 MDR MRP ALD OABP GCN20 White 
Subfamily ABCA ABCB ABCC ABCD ABCE ABCF ABCG 
Members 12 11 12 4 1 3 5 
 
 
 
Table 1-2  New nomenclature for the ABC transporter proteins  
Old nomenclature for the 
gene 
New nomenclature for the 
gene  
Protein encoded by the 
gene 
MDR1 ABCB1 P-gp 
BCRP / MXR/ABCP ABCG2 BCRP / MXR/ABCP 
MRP ABCC1-6 MRP 1-6  
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1.2. P-glycoprotein (P-gp) 
  P-gp is encoded by the ABCB1 gene which belongs to the adenosine 5’-
triphosphate (ATP) binding cassette superfamily of proteins known as ABC 
transporters.  The proteins belonging to this superfamily utilize ATP as the energy 
source to carry out the active efflux of xenobiotics.  P-gp is a 1280 amino acid 
transmembrane protein with a molecular weight of 170 kDa.  The ABCB1 gene has 
been mapped to choromosome 7q21.1 [2;3].  Structurally, P-gp has a total of 12 
transmembrane domains divided into homologous regions (Figure 1.1).  Each half 
contains 6 transmembrane domains and an intracellular ATP binding domain (also 
known as a nucleotide binding domain) [4].  These transmembrane domains bind to 
hydrophobic drugs and pump them out of cells.  The development of resistance to 
chemotherapeutic agents in some tumor cells is attributable to the active efflux of 
these agents by P-gp.  This efflux utilizes the energy from ATP hydrolysis.  With the 
help of stoichiometric studies it has been shown that two ATP molecules are 
hydrolyzed for the transport of each substrate molecule [5;6].  However both these 
events do not take place simultaneously, rather there are two independent ATP 
hydrolysis events in a single catalytic cycle [7].  Hydrolysis of one ATP molecule 
results in transport of the substrate whereas the other causes a conformational change 
necessary to reset the efflux pump for the next catalytic cycle [7]. 
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Figure 1-1  Schematic representation of ABC efflux transporter structure 
The structures of ABC efflux transporters: P-gp (A), encoded by ABCB1 gene, which has 
12 transmembrane domains and two ATP binding sites and ABCP (B), encoded by 
ABCG2 gene, which has 6 transmembrane domains and one ATP binding site.  The N-
terminal is the amino terminal and C-terminal is the carboxy terminal.  Figure adapted 
from Gottesman et al. [8]. 
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1.2.1. Tissue Distribution and Function of P-gp 
  P-gp is present not only in tumor cells but also in normal tissues [9] and 
plays a very important role in the absorption, distribution and excretion of drugs.  It is 
expressed in the intestinal epithelium whereby it pumps drugs back into the gut 
lumen, thus affecting absorption and decreasing oral bioavailability.  Located at the 
apical membranes of hepatocytes and proximal tubules of the kidney, P-gp transports 
drugs into bile and urine, respectively, thus facilitating their biliary and urinary 
elimination.  The blood brain barrier (BBB) prevents a variety of xenobiotics from 
entering the brain and helping prevent central nervous system (CNS) toxicity.  P-gp is 
located on the luminal surface of the capillary endothelium of the BBB and facilitates 
efflux of xenobiotics back into the blood, thus reducing CNS exposure.   
  Animal models have been utilized to study the role of P-gp in the transport 
of xenobiotics.  Although humans express a single ABCB1 gene, there are two highly 
homologous mdr1 genes in mice, termed mdr1a and mdr1b.  Substantial overlap is 
seen in substrate specificity and tissue distribution between the P-gp’s from mouse 
and human and therefore these transporters are believed to play similar roles in these 
species [10].  Due to these similarities, an mdr knockout (KO) mouse, created by a 
targeted disruption of the mdr gene, has proven to be a very useful model to study the 
contributions of P-gp in drug pharmacology.  Kim et al. [11] in a study with KO mice 
demonstrated that plasma levels of HIV protease inhibitors like indinavir, saquinavir 
and nelfinavir, P-gp substrates, were 2 - 5 times higher in mdr1a KO mice as 
compared to wild type (WT) mice.  In addition, these investigators also found the 
concentrations of these drugs to be 7-36 fold higher in the brains of KO mice after 
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intravenous administration as compared to WT.  A subpopulation of CF-1 mice that is 
naturally deficient in mdr1a has also been used in similar studies to understand the 
role of P-gp as these mice are phenotypically similar to the mdr KO mice.  Kwei et al. 
[12] used these mdr1a deficient mice to investigate the disposition of ivermectin and 
cyclosporin A.  Higher concentrations of ivermectin and cyclosporin A were seen in 
the brain and blood of mdr1a deficient mice as compared to CF-1 WT mice after 
intravenous or oral administration.  These studies demonstrated that P-gp not only 
governs the absorption and distribution of drugs but also plays a protective role by 
preventing the transport of drugs across the BBB.  In addition to being expressed at 
the brain capillary endothelium, P-gp is also expressed in placenta.  Lankas et al. 
performed studies in the mdr1a deficient mice and its findings provided evidence for 
the role of placental P-gp in protection of the developing fetus [13].  An isomer of the 
pesticide avermectin, a substrate for P-gp, is known to produce cleft palate.  The 
pregnant dams were exposed to this isomer and the susceptibility of the fetus to 
develop cleft palate was determined.  The homozygous fetuses (+/+), which had 
abundant P-gp, were totally insensitive to this teratogen whereas the homozygous 
fetuses (-/-), which were deficient in P-gp, were completely susceptible to developing 
cleft palate.  The heterozygote fetuses (+/-) had a moderate effect due to intermediate 
expression levels of P-gp [13].  Since mice have two mdr genes, mdr1a and mdr1b, it 
was thought that mdr1b would be upregulated in the mdr1a KO mice as a 
compensatory mechanism.  Therefore to nullify all mdr activity, Smit et al. used KO 
mice in which both the mdr genes, mdr1a and mdr1b, were disrupted.  These mice 
were used to study the transport of P-gp substrates digoxin, saquinavir and paclitaxel 
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in pregnant heterozygous mdr mice [10].  They demonstrated that the placental P-gp 
reduced the transfer of drugs to the fetus with the most reduction found in the WT 
fetuses (mdr1a+/+ / 1b+/+) as compared to heterozygous fetuses (mdr1a+/- / 1b+/-) and 
KO fetuses (mdr1a-/- / 1b-/-).  They further demonstrated that after oral administration 
of P-gp inhibitors like PSC833 or GF120918, drug levels in WT mice were 
comparable to KO mice and much higher than WT vehicle treated mice.  These 
studies demonstrate the importance of placental P-gp in limiting the fetal exposure of 
potential chemical teratogens.  It also suggests that modulation of placental P-gp can 
increase the transfer of drugs across the placenta to the fetus if the fetus is the patient 
and transfer is desirable for a therapeutic outcome.   
 
 
1.2.2. Substrates and Inhibitors of P-gp 
  The phenomenon of multidrug resistance found during the treatment of 
cancer has been partly attributed to transporters such as P-gp.  P-gp is involved in the 
transport of a large variety of drugs used for numerous disorders including cancer 
(doxorubicin, vinblastine, paclitaxel) and AIDS (amprenavir, saquinavir).  An 
extensive list can be found at www.aidsinfonyc.org.  These drugs differ not only 
functionally but also structurally.  Most of the drug substrates are hydrophobic but 
can be neutral or positively charged.  To understand the broad substrate specificity, 
researchers have carried out mutation analysis, which demonstrated that mutations in 
the transmembrane domains affect P-gp functionality.  These results suggest that the 
binding sites are broad regions of recognition [14].  In addition, Martin et al. [15] 
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have demonstrated, using several substrates and modulators of P-gp in radioligand 
binding studies, that P-gp has a minimum of four distinct drug binding sites and there 
is an allosteric interaction between the sites.   
  Inhibition of P-gp to increase the effectiveness of cancer chemotherapeutic 
agents is thought of as one route of decreasing multidrug resistance.  The first 
generation of P-gp inhibitors (cyclosporin A, verapamil) were drugs that were used 
for other therapeutic purposes.  Due to toxicity issues, a second generation of 
inhibitors for e.g. PSC833, which are analogs of the first generation agents for e.g. 
cyclosporin A were developed.  LY335979 is by far the most potent and selective 
inhibitor of P-gp.  A thorough review of interactions of P-gp with its substrates and 
inhibitors has been presented by Litman et al. [14]. 
 
 
1.2.3. Induction, regulation and drug-drug interactions of P-gp 
  Many P-gp substrates are also P-gp inducers.  In LS180/WT and its 
adriamycin resistant subline LS180/AD50, P-gp was upregulated after treatment with 
various drugs including rifampin, phenobarbital, clotriamazole, reserpine, midazolam, 
nifedipine and isosafrole.  An increase in ABCB1 mRNA on treatment with rifampin 
and reserpine suggested that P-gp is upregulated at the transcriptional level rather 
than at the post-translational level [16].  ABCB1 mRNA was also upregulated by 
polycyclic aromatic hydrocarbons (PAHs) like 3-methylcholanthrene (3-MC) and 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in primary human hepatocytes.  
However a polymorphic inducibility was seen where 3-MC and TCDD induced 
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ABCB1 mRNA in only 62% and 55% of the preparations respectively.  These results 
suggest that although aromatic hydrocarbons upregulate ABCB1, the induction does 
not occur via the classical Ah receptor pathway [17].  Polli et al. [18] have 
demonstrated that HIV protease inhibitors like amprenavir and nelfinavir are not only 
substrates of P-gp but also induce P-gp.  Western blot analysis revealed that 
amprenavir and nelfinavir both increased the expression of intestinal P-gp but not of 
hepatic P-gp in rats, suggesting a tissue specific induction.  The difference in P-gp 
induction could also be due to reduced concentrations of these drugs reaching P-gp in 
the liver as they might be metabolized by hepatic CYP3A4, which itself is induced by 
these drugs.   
  Due to its wide substrate specificity and inducibility, P-gp plays a very 
important role in drug-drug interactions.  In-vitro experiments and animal studies 
have shown that fexofenadine [19] and digoxin [20;21] both are substrates for P-gp 
and are primarily excreted unmetabolized.  Concomitant administration of rifampin 
with digoxin reduced the oral bioavailability of digoxin in healthy males by 30% and 
a 3.5 fold increase was seen in intestinal P-gp expression [22].  Similarly Hamman et 
al. have shown that rifampin therapy reduced the bioavailability of fexofenadine, 
which they attributed to the induction of intestinal P-gp [23].   
  Recent studies have helped us understand the mechanism of regulation of 
P-gp at the molecular level.  Synold et al. [24] have recently shown that the pregnane 
X receptor (PXR), a nuclear hormone receptor, regulates drug efflux by activating the 
expression of the ABCB1 gene.  Paclitaxel (taxol), a commonly used antineoplastic 
agent is an efficient and selective activator of PXR and induces ABCB1 mediated 
 10
drug efflux.  However, docetaxel (taxotere), an analog of paclitaxel, did not activate 
PXR or induce the ABCB1 mediated drug efflux.  Ecteinascidin-743 (ET-743) is an 
antineoplastic agent and has been shown to inhibit trichostatin-induced transcription 
of ABCB1 [25;26].  Synold et al. [24] found that ET-743 can repress the ligand 
mediated activation of PXR thus inhibiting the transcriptional activation of ABCB1.  
In addition, Geick et al. found PXR response elements, essential for ABCB1 induction 
by rifampin, to be present in the upstream region of human ABCB1 [27].  These 
studies support the role of PXR in regulation of P-gp, however, it might not be solely 
responsible for P-gp induction and other regulatory pathways may exist given that P-
gp is also induced by some Ah receptor ligands.   
 
 
1.2.4. Genetic Polymorphism in P-gp 
  As mentioned above, phenotypic variability was reported in the induction 
of P-gp by PAHs [17].  In addition, substantial interindividual variability was seen in 
expression of hepatic P-gp within and between males and females [28].  Also, 
disposition of P-gp substrates varies between individuals [29;30] and this could be 
important for drugs with narrow therapeutic indices.  These reports underscore the 
importance of genotyping studies to determine if any polymorphisms exist that may 
explain the observed inter-individual differences.  In-vitro studies have suggested that 
amino acid changes in the ABCB1 gene leads to altered activity [31;32].  A total of 15 
polymorphisms were identified by Hoffmeyer et al. in the ABCB1 gene in a 
Caucasian population.  The authors demonstrated a significant correlation between 
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the single nucleotide polymorphism (SNP) at exon 26 (C3435T) and P-gp expression 
and activity in the duodenum.  Individuals with the T/T allele had lower P-gp 
expression and higher plasma concentrations of digoxin [33].  P-gp genotyping 
studies in Japanese women showed that in addition to the SNP at exon 26 (C3435T), 
which was present in 93.8% of women in the study, these individuals also had a SNP 
at exon 21 G2677 (A/T) [34].  This suggests an association between these two SNPs.  
Later, Kim et al. [35] found the following 3 SNPs to be present simultaneously in 62 
% of European Americans and 13% of African Americans: C1236T in exon 12, 
G2677T in exon 21 and C3435T in exon 26.  Using fexofenadine as a probe drug, 
these individuals were phenotyped for P-gp activity.  The results suggested that the 
individuals who had the T/T homozygous allele in both exon 21 and exon 26 had 
lower plasma concentrations of fexofenadine suggesting an increased expression of P-
gp as compared to the individuals containing the homozygous G/G and C/C allele in 
exon 21 and exon 26, respectively.  These results are however contradictory to the 
results published by Hoffmeyer et al. [33] and Tanabe et al. [34].  Thus, the effects of 
genetic polymorphisms with respect to the direction of change in P-gp expression and 
activity are still unclear.  Further studies are needed to understand the effect of these 
polymorphisms not only on the level of expression but also the functional activity of 
P-gp.   
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1.3. ABCP (BCRP / MXR) 
  Placenta-specific ATP binding cassette gene (ABCP) [36] also known as 
breast cancer resistance protein (BCRP) [37] or mitoxantrone resistance associated 
protein (MXR) [38], is encoded by ABCG2 which belongs to the ABCG subfamily.  
ABCG2 gene is located on chromosome 4q22.  ABCP is a 655 amino acid 
transmembrane protein with a molecular weight of 70 kDa.  ABCP utilizes energy 
from ATP hydrolysis to function as an efflux transporter.  It has only 6 
transmembrane domains and an intracellular ATP binding domain towards the N-
terminal (Figure 1.1).  ABCP exists as a half transporter and is half the size of other 
ABC transporters like P-gp which has 12 transmembrane domain and two ATP 
binding domains.  The half transporters usually dimerize to become functional and 
ABCP is assumed to be a functional dimer.  Though no dimerization partner has been 
identified so far, current transfection data suggest it is functional as a homodimer 
[14].  It was reported that ABCP migrates as a 70 kDa protein under reducing 
conditions and as a 140 kDa complex under non-reducing conditions.  These results 
suggest that ABCP forms a homodimer via the disulfide linkage [39].   
 
 
1.3.1. Substrates and Inhibitors of ABCP 
  ABCP offers resistance to a variety of substrates and exhibits considerable 
substrate overlap with P-gp, as shown in Figure 1.2 adapted from Litman et al. [14].  
Mitoxantrone and topotecan are good substrates for ABCP and overexpression of 
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ABCP has been reported in both mitoxantrone and topotecan resistant cells [40;41].  
A number of functional assays have been developed to determine the functional 
activity of ABCP and to screen for drugs that interact with the protein.  Some of the 
substrates that are transported by ABCP are the anthracyclines, SN-38 [42], 
bisantrene, rhodamine 123, LysoTracker Green, prazosin and its fluorescent analog 
BODIPY-prazosin [43].   
  Fumitermorgin C (FTC) [44] and GF120918 [45] are effective inhibitors 
of ABCP and increase the intracellular accumulation of ABCP substrates in ABCP 
overexpressing cells.  FTC is a potent and selective inhibitor of ABCP whereas 
GF120918 is a potent inhibitor but not selective and is know to inhibit P-gp as well.  
More than 20 analogs of FTC have been analyzed for their inhibitory action on ABCP 
but none had equal or better activity or selectivity than FTC for ABCP [46].  
Recently, it was demonstrated that estrone and 17β-estradiol also inhibit ABCP and 
increase the intracellular accumulation of topotecan in drug resistant cells that 
overexpress ABCP [47].   
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Figure 1-2  Venn diagram showing the substrate overlap between P-gp and ABCP   
Abbreviations: BIS, bisantrene; CPT-11, Topotecan; DNR, daunorubicin; DOX, 
doxorubicin; EPI, epirubicin; LYS, LysoTracker; MX, mitoxantrone; PRA, prazosin; 
RHO, rhodamine 123; SN-38, metabolite of CPT-11; TXL, taxol; TOP, topotecan; VBL, 
vinblastine; VCR, vincristine; VER, verapamil.  Figure adapated from Litman et al. [14].   
 
 15
1.3.2. Tissue distribution, location and function of ABCP 
  Observation of drug resistance and reduced drug accumulation in 
multidrug tumor cells which did not show overexpression of P-gp or MRPs led to the 
discovery of ABCP, a new member of ABC superfamily of transporters.  These cell 
lines are derived from breast cancer [37], ovarian carcinoma [41] and colon 
carcinoma cells [44].  Using immunohistochemical staining, ABCP has been 
predominantly localized to plasma membranes [48].  Apart from being expressed in 
cancerous tissue, ABCP has also been reported to be present in normal tissues.  
Tissue distribution of ABCG2 mRNA was determined by northern blotting and found 
to be present predominantly in placenta and to a lesser extent in brain, small intestine, 
liver, colon ovary, testis and prostate [37].  ABCP protein has also been reported to be 
expressed prominently in placenta, liver, small intestine and colon of humans [49].  
This expression corresponded with ABCG2 mRNA levels measured by RT-PCR.  The 
murine breast cancer resistance protein (bcrp1) is highly homologous to human 
ABCP with 81% amino acid identity [50].  The bcrp1 mRNA was however found to 
be highly expressed in kidney and to a lesser extent in placenta as compared to 
humans [51].  A new multidrug resistance protein has been identified in porcine brain 
capillary endothelial cells that is closely related to ABCP with 86% amino acid 
identity [52].  The tissue distribution of ABCP is similar to P-gp distribution and 
suggests it may play a role in the absorption, distribution and elimination of drugs.  
Its substantial expression in placenta also suggests ABCP may serve as a protective 
barrier which prevents the transport of its substrates across the placenta and to the 
fetus.  In order to understand the role of bcrp in placenta, Jonker et al. [51] measured 
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the bioavailability of topotecan in fetuses of wild type mice and mdr1a/1b knockout 
mice.  The mdr1a/1b knockout mice were used to control for the contribution of P-gp, 
since some overlap in substrate specificity exists.  The authors reported that the 
bioavailability of topotecan in the presence of GF120918, an ABCP and P-gp 
inhibitor, was six fold higher in KO mice and nine times more in the WT mice as 
compared to the respective vehicle treated mice.  Also, a two fold higher fetal 
exposure of topotecan was seen in KO mice treated with GF12098 than in vehicle 
treated KO mice [51].  These results suggest an important role for bcrp in fetal 
exposure to drugs.  To date, there are no reports on functionality of ABCP in human 
placenta.  However, with the knowledge that ABCP is highly expressesed in human 
placenta and that there is homology between the mouse bcrp and human ABCP, one 
can assume that ABCP in addition to P-gp plays an important role in limiting the fetal 
exposure to various xenobiotics during pregnancy.   
 
 
1.3.3. Mutations / polymorphisms in ABCP 
  Of the 9 cell lines studied, Rhodamine 123, a substrate for ABCP, was 
transported in some but not all ABCP overexpressing cells whereas mitoxantrone was 
transported in all cell lines.  On seqencing the genomic DNA, mutations in the amino 
acid at position 482 were found.  The wild type ABCP has an arginine (R) at postion 
482 whereas some cells had either threonine (T) or glycine (G) at this position.  The 
mutated cells (R482T or R482G) were able to carry out the transport of rhodamine 
123 in contrast to the wild type cells.  The transport of doxorubicin also was shown to 
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be affected by the mutations.  These results suggest that the amino acid at position 
482 may be critical in binding of the substrate to the transporter, thus affecting 
substrate transport.  It should also be noted that the mutational effects observed are 
substrate dependent.  As these mutations change the substrate specificity they may 
lead to alterations in drug resistance phenotype [53].  Recently, similar results were 
seen in mouse cell lines overexpressing bcrp1.  Mutations at position 482 were seen, 
however, in murine cells arginine was replaced by methionine (M) and serine (S) [54] 
as opposed to threonine and glycine in humans.  Genotyping studies to determine if 
such polymorphisms exist in normal human tissues are needed and should be 
accompanied by phenotyping studies to understand the impact of these amino acid 
changes in function of ABCP.  Recently, Zamber et al. [55] performed an ABCP 
genotyping study using human intestinal samples from 11 different ethnic populations 
and have reported the presence of several SNPs, with G34A and C421A being the 
two most frequent SNPs observed.  Interestingly, the mutations observed in the drug 
selected cell lines resulting in an amino acid change at position 482 were not detected 
in any of the human intestinal samples and thus were attributed to acquired mutations 
due to drug selection.  There was significant variation in the expression of ABCP 
mRNA and protein between individuals and on an average expression was higher in 
females than males.  However, no correlation was observed between the most 
frequent polymorphisms and the level of ABCP expression.  Whether these 
polymorphisms have an effect on ABCP function in humans is yet to be determined.   
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1.4. Cytochrome P450 1A1 (CYP1A1) 
  The human CYP1 family contains CYP1A1, CYP1A2 and CYP1B1 
[56;57].  CYP1A2 is found primarily in hepatic tissue whereas CYP1A1 and 
CYP1B1 are extrahepatic in nature. CYP1A1 and CYP1A2 belong to the CYP1A 
subfamily and are approximately 68% identical in their sequence [58].   
  CYP1A1, also known as aromatic hydrocarbon hydroxylase, is responsible 
for metabolism of environmental carcinogens such as polycyclic aromatic 
hydrocarbons (PAH).  Benzo[a]pyrene, a PAH, is principle constituent of cigarette 
smoke.  It is a procarcinogen and is metabolized by CYP1A1 to mutagenic and 
carcinogenic compounds.  CYP1A1 is highly inducible by PAHs, cigarette smoking 
and polychlorinated biphenyls (PCB).  The mechanism of induction of CYP1A 
enzymes is well studied and understood.  The inducing agent (ligand) binds to 
cytosolic aromatic hormone receptor (Ah receptor) and this receptor is translocated to 
the nucleus where it binds to Ah receptor nuclear translocator (ARNT) protein.  This 
complex then binds to the DNA of the CYP1A1 gene and enhances its rate of 
transcription.  There is inter-individual variability in the induction of CYP1A1 which 
might be related to the genetic differences in the Ah receptor expression [59].   
  Of the CYP1A family, CYP1A1 and CYP1B1 are found in human 
placenta.  CYP1A2 is not found in placenta; however, its mRNA can be detected in 
the first trimester (10-12 weeks of gestation) of pregnancy.  CYP1A1 mRNA as well 
as the protein has been found in full term placentas [60;61].  The 7-ethoxyresorufin 
O-deethylase (EROD) reaction is mainly catalyzed by CYP1A1 and is used as an 
activity marker for this enzyme.  Constitutive CYP1A1 activity is very low or 
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unmeasurable in placentas, however, this activity increases with maternal cigarette 
smoking [62].  CYP1A1 gets induced to a variable extent depending on stage of 
pregnancy with the highest activity being seen at term [63].  Immunohistochemical 
analysis has shown that the cigarette smoke induced CYP1A1 is localized over both 
synctiotrophoblastic and cytotrophoblastic areas [64] of the placenta.   
 
 20
1.5. Placenta 
  The placenta is the sole link between the mother and the fetus. It carries 
out the transport of essential nutrients, oxygen and water from mother to the fetus as 
well as removing waste products from the fetus.  It performs the necessary functions 
of several fetal organs such as the liver, lungs, kidney etc. until these organs are fully 
developed.  The placenta is a disc shaped tissue and has two plates namely chorionic 
and basal plate which faces the fetus and mother, respectively [65].  Villous tissue 
present between these two plates is perfused with maternal blood.  The placental villi 
are tree like structures originating from the chorionic plate and are lined with 
trophoblastic cells [66].  Transfer of xenobiotics across the placenta proceeds both 
passively and via various transporters that are expressed in villi in a polarized fashion.  
These transporters are expressed differentially in the maternal-facing brush border 
and the fetal-facing basal membrane of syncytiotrophoblast (ST) cells, which is 
known as the functional unit of placenta.  ST is multinucleated and is formed as the 
pregnancy advances by the fusion of uninucleated cytotrophoblastic cells.  In addition 
to physiological substrates, the transporters present in the membranes of ST also 
transport xenobiotics which include therapeutic agents, environmental pollutants and 
drugs of abuse.  Therapeutic agents used to treat the mother may cross the placental 
barrier and have untoward effects on the fetus.  On the other hand, in cases such as 
where the fetus is HIV infected, placental transfer of therapeutic agents is desirable 
for a positive therapeutic outcome.  In addition to transporters, there are also some 
drug metabolizing enzymes present in the placenta which alter the passage of 
xenobiotics across the placenta.  These enzymes primarily metabolize xenobiotics to 
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make them more water soluble and thus increase their elimination; however, toxic 
and / or reactive metabolites may also be produced.   
  The brush border membrane of the ST faces the mother and is in direct 
contact with maternal blood whereas the basal membrane faces the fetal blood 
circulation.  The brush border (microvillus) membrane is made up of microvilli that 
increase the surface area of the membrane.  There is evidence of efflux transporters, 
belonging to the ABC superfamily of proteins, such as P-gp, ABCP and some of the 
MRPs, being present in the microvillus membrane of the placenta.  Due to their efflux 
nature, these transporters expressed in microvillus membranes can pump xenobiotics 
back to mother and thus may prevent fetal toxicity.   
  P-gp is abundantly expressed in human placental trophoblast cells [9;67] 
and this expression is selectively seen in trophoblast cells of first trimester placenta.  
In full term placenta, P-gp was found in Hofbauer cells and placental macrophages.  
However, Nakamura et al. also demonstrated the presence of P-gp in trophoblasts 
from full term placenta [68].  Uptake of radiolabeled vincristine in microvillus 
membrane vesicles isolated from trophoblast cells confirmed the expression of active 
P-gp in the placenta.  However, these investigators reported a smaller size P-gp (160 
kDa) to be present in trophoblast, whereas others have reported a 170 kDa P-gp in 
primary human cytotrophoblasts [69] which could be due to differences in post-
translational modifications such as glycosylation.  Primary cultures of human 
cytotrophoblasts and BeWo cells, a choriocarcinoma cell line, have also been used to 
study the functional expression of P-gp [69;70].   
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  Apart from P-gp, other multidrug transporters are also present in placenta.  
With the help of sensitive molecular techniques, multidrug resistance associated 
protein (MRP) was found to be present in human placenta.  At least 3 different MRP 
mRNAs have been identified in placenta [71].  MRP1 and MRP5 are present and 
functionally active in BeWo cells [72] and are involved in the transport of 
unconjugated bilirubin.  The most recently discovered ABC efflux transporter, ABCP 
(BCRP / MXR), is reported to be highly expressed in the plasma membrane of 
syncytiotrophoblastic cells of the placenta [73].  High endogenous expression of 
ABCP was also found in the human choriocarcinoma cell lines JAR, JEG-3 and 
BeWo [74].  However, there are no reports on the functionality of ABCP in human 
tissues and whether this protein is functional in placenta is yet to be determined.   
 
 
1.6. Effect of smoking on placenta and placental enzymes and 
transporters 
  Cigarette smoking has been associated with adverse outcomes during 
pregnancy including changes in function and structure of the placenta.  Furthermore, 
increased fetal morbidity and mortality have been reported due to maternal smoking.  
Morphologically, changes such as thickening of the trophoblastic cells and decrease 
in volume density of fetal capillaries within terminal villi have been observed in 
smokers [75].   
  Smoking and associated polycyclic aromatic hydrocarbons (PAHs) can 
affect drug metabolizing enzymes expressed in placenta.  The constitutive expression 
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of CYP1A1 is low in placenta but is readily induced by xenobiotics.  PAHs found in 
cigarette smoke are good inducers of CYP1A1, and high and variable CYP1A1 
activity has been reported in placental microsomes from smokers as compared to non-
smokers [62].   
  To date, the effect of smoking on efflux transporters expressed in placenta 
has not been reported.  P-gp, however, has been shown to be induced by various 
PAHs in rat and mouse liver.  Of the PAHs studied, 3-MC and 2-acetylaminofluorene 
induced P-gp mRNA levels in primary cultures of hepatocytes in rats, however, 
TCDD was unable to induce P-gp mRNA levels at relevant concentrations of TCDD 
[76].  Similarly, in mouse liver, P-gp mRNA levels were induced by 3-MC but not by 
TCDD [77].  Interestingly, 3-MC and TCDD both induced P-gp mRNA levels in 
primary cultures of human hepatocytes.  However, a phenotypic variability was seen 
in the induction [17] as only 62% and 55% of the primary hepatocyte cultures showed 
induction after treatment with 3-MC and TCDD respectively.  Thus, in-vitro animal 
and human studies suggest that PAHs induce P-gp mRNA in liver, however, whether 
similar induction occurs in placenta is not known.  In addition, PAH benzo-[a]-
pyrene, apart from being a substrate for CYP1A1, is also a substrate for P-gp [78].  
Thus, analogous to the induction of CYP1A1, there could possibly be induction of P-
gp levels in placentas of women who smoke during pregnancy, resulting in a 
protection of the fetus from the harmful effects of cigarette smoke constituents.  Thus, 
we hypothesized that smoking might increase P-gp levels in human placenta.  ABCP, 
another efflux transporter expressed in placenta, is also believed to play a protective 
role in placenta similar to P-gp.  However there are no reports of functional studies of 
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ABCP in human placenta and its regulation by cigarette smoke constituents. Thus, we 
studied the function and expression of P-gp and ABCP in placentas from smokers and 
non-smokers.   
 
1.7. Specific aims of this research 
 
1. Compare levels of P-gp activity and expression in human placentas from smokers 
and non-smokers. 
2. Correlate levels of P-gp and CYP1A1 in human placentas from smokers and non-
smokers.   
3. Compare levels of ABCP activity and expression in human placentas from 
smokers and non-smokers. 
4. Evaluate the induction of P-gp by various xenobiotics in choriocarcinoma and 
colon carcinoma cell lines. 
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CHAPTER II 
2. EXPERIMENTAL 
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2.1. Patient Selection 
 Subjects were recruited through the Obstetrics and Gynecology Department at 
Ruby Memorial Hospital at West Virginia University.  Placental samples were obtained 
using a protocol approved by the West Virginia University Institutional Review Board for 
the Protection of Human Research Subjects (Figure 2.1 and 2.2).  Participants provided 
informed written consent prior to obstetric delivery.  Placentas were collected from 
women (ages 18-36 years) who were full term (38 weeks and more).  Subjects were 
smoking and non-smoking females with no concurrent disease states.  Smoking status 
was determined via patient interview.   
 
 
2.2. Tissue Collection 
 Placentas were collected and processed immediately after delivery.  Two 
triangular wedges extending from center of the placenta to the placental margin were 
removed for processing.  One piece was placed in a plastic bag, appropriately labeled and 
frozen at -80°C for later preparation of placental microsomes.  The other piece was 
immediately processed to prepare the membrane vesicles.   
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 Figure 2-1  Consent Form (Page 1) 
Consent form for placental transport of drugs approved by West Virginia University 
Institutional Review Board for the Protection of Human Research Subjects 
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Figure 2-2  Consent Form (Page 2)  
Consent form for placental transport of drugs approved by West Virginia University 
Institutional Review Board for the Protection of Human Research Subjects 
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2.3. Preparation of Microvillus and Basal Membrane Vesicles 
Microvillous membrane vesicles (MVM) and basal membrane vesicles (BMV) 
were prepared simultaneously from the same placenta within 30 min of delivery using a 
homogenization and differential centrifugation technique conducted according to the 
methods of Illsley et al. [79].  The tissue was cut into small pieces and washed several 
times in 0.9% NaCl.  The washed tissue was further minced finely and suspended in 3 
volumes of buffer 1.  The suspension was homogenized in 25 ml aliquots for 2 min using 
a Virtisher tissue homogenizer and this was labeled as homogenate 1 which was 
centrifuged at 10,000 g for 15 min.  The supernatant (supernatant 1) was collected and 
the pellet resuspended in buffer 1, homogenized (homogenate 2) and centrifuged again.  
Both supernatant fractions were then combined, filtered through gauze and centrifuged at 
47,500 g for 1 h. The pellet was resuspended in buffer 1 (15 mg/ml) and to this MgCl2 
was added (12 mM final concentration).  The mixture was stirred on ice for 20 min and 
centrifuged at 2500 g for 15 min.  The supernatant and Mg2+ aggregated pellet was 
further processed to get the MVM and BMV respectively.  The supernatant was 
centrifuged at 47,500 g for 30 min.  The obtained pellet (MVM) was washed and 
resuspended in buffer 2 after passage through a 25-gauge needle, aliquoted and stored at -
80°C.  The Mg2+ aggregated pellet was resuspended in buffer 2, homogenized thoroughly 
and 15 ml was layered onto a sucrose step gradient.  The step gradient was constructed in 
40ml Beckman SW 28 centrifuge tubes using a bottom fraction (6 ml) with density 1.190 
gm/cm3 and a middle fraction (17 ml) with density 1.165 gm/cm3.  The gradient was 
centrifuged for 1 hour at 141,000 g using a Beckman SW 28 swing-out rotor with a slow 
acceleration and deceleration through 140 rpm.  The resulting fraction at the interface of 
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the bottom and middle steps was collected.  This fraction was diluted with 10 volumes of 
buffer 2, homogenized and centrifuged at 47,500 g for 30 min.  The pellet (BMV) was 
resuspended in buffer 2 after passage through a 25-gauge needle, aliquoted and stored at -
80°C.  The entire procedure was carried out at 4°C. 
 
 
Buffer 1:   
Buffer 1 consists of 10 mM Tris HCl – Hepes (pH 7.0), 250 mM sucrose, 5 mM EGTA, 5 
mM EDTA and 1 mM PMSF.   
 
Buffer 2:   
Buffer 2 consists of 10 mM Tris HCl - Hepes (pH 7.4) and 250 mM sucrose.   
 
 
2.4. BCA Protein Assay 
 Membrane vesicle protein concentrations were determined using the BCA protein 
assay kit from Pierce.  The assay was carried out in a 96 well, flat bottom polystyrene 
(clear) microtiter plate.  Samples were diluted 1:10 (10 µL sample and 90 µL of distilled 
H2O) and 1:20 (5 µL sample and 95 µL of distilled H2O) with water and then vortexed.  
20 µL of standards (Bovine serum albumin 125 µg/mL – 2000 µg/mL) and diluted 
samples were pipetted in appropriate wells (n = 3).  The BCA reagents were prepared 
according to the manufacturers instructions and 200 µL/well was added by means of an 
Eppendorf repeating pipettor.  The plate was shaken to mix the solutions and then 
incubated at 37°C for 30 min.  After allowing the plate to cool to room temperature, the 
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absorbance was read at 562 nm on a Thermomax plate reader using Softmax Pro 
software.   
 
BCA protein reagents  
Immediately prior to use, mix 1 part of reagent B (0.5 ml) with 50 parts of reagent A (25 
ml). 
 
 
2.5. Sialic Acid Assay for Sidedness or Orientation of Membrane 
Vesicles 
 The percentage of inside-out vesicles was determined by the accessibility of 
sialidase to sialic acid in the presence and absence of detergent.  Briefly, aliquots of 
vesicles containing 100 - 300 µg of protein in 50 µL were incubated at 37°C for 30 min 
with an equal volume of sialidase reagent with or without 0.2% Triton X-100 (detergent) 
[80].  The samples were centrifuged at 10,000 rpm for 5 min and the supernatant used to 
measure the sialic acid released using a combination of the methods of Warren et al. [81] 
and Aminoff et al. [82].  Briefly, 0.5 ml of sample / standard was incubated at 37°C with 
0.25 ml of the periodate reagent for 30 min.  At the end of 30 min, the tubes were taken 
out of water bath and 0.2 ml of sodium arsenite solution was added to reduce the excess 
periodate.  The tubes were then vortexed until the yellow color of the liberated iodine 
disappeared (2 min).  As soon as the yellow color disappeared, 2 ml of thiobarbituric acid 
reagent was added, tubes were capped, vortexed and placed in a boiling water bath for 10 
min.  At the end of 10 min, the tubes were placed in ice water for 5 min and then shaken 
 32
with 3 ml of cyclohexanone.  The tubes were then centrifuged at 3000 rpm for 3 min and 
the upper organic layer collected.  The organic layer was transferred to a cuvette and the 
absorbance was measured at 549 nm using a Hitachi U-2000 UV spectrophotometer.  The 
amount of sialic acid released in the samples was calculated from the slope of the 
standard curve generated using N-acetylneuraminic acid (20 µg/ml – 320 µg/ml).   
 
Calculations 
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Periodate Reagent 
Periodate reagent consists of 0.2 M sodium m-periodate, 9 M phosphoric acid. 
Dissolve sodium m-periodate in water first and then add the phosphoric acid. 
Store at room temperature. 
 
 
Sodium arsenite reagent: 
Sodium arsenite reagent consists of 0.5 M sodium sulfate, 0.1 M H2SO4 and 10% sodium 
arsenite. 
Store at room temperature. 
 
 
Thiobarbituric acid reagent: 
Thiobarbituric acid reagent consists of 0.1 M thiobarbituric acid with the pH adjusted to 
pH 9.0 with 10 N NaOH. 
Store at 4°C in a refrigerator. 
 
Sialidase Stock: 
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Type VI neuraminidase from Clostridium perfringens (Sigma) is stored as 1 mg/ml 
solution in 0.3 mg/ml bovine serum albumin in refrigerator. 
 
Sialidase Reagent: 
0.1 mg/ml of sialidase in 0.1 M Tris-acetate buffer pH 5.0.  Store in refrigerator. 
 
Sialidase and Triton reagent: 
Sialidase reagent + 0.2% (v/v) Triton X-100. Store in refrigerator. 
 
 
2.6. Alkaline Phosphatase Assay 
Alkaline phosphatase is a marker enzyme localized in the microvillus membrane 
of cells. It catalyzes the formation of p-nitrophenol from p-nitrophenylphosphate [83].  
An alkaline phosphatase assay can be used to determine the enrichment of microvillus 
membrane when isolating membranes from cells or tissue homogenates [79] as well as to 
measure the orientation of membrane vesicles.   
 
2.6.1. For determination of enrichment of the microvillus membrane 
 To determine the enrichment of the microvillus membrane, aliquots from various 
stages of the membrane vesicle preparation procedure were saved including homogenate 
1, supernatant 1, homogenate 2and the final microvillus membrane pellet.  The protein 
concentration of these samples was determined using the BCA protein assay.  All the 
above mentioned fractions and the final microvillus membrane pellet were diluted to 
achieve a protein concentration of 2.5 mg/ml and further diluted to 1:2000 with 
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diethanolamine / MgCl2 buffer.  20 µL of the diluted samples were aliquoted into a 96 
well plate and to this 50 µL of diethanolamine / MgCl2 buffer containing 5 mM p-
nitrophenylphosphate were added.  After mixing, the plate was incubated at 37°C for 30 
min and the absorbance read at 405 nm using a Thermomax plate reader.  The amount of 
p-nitrophenol formed was calculated from a standard curve generated using p-nitrophenol 
(40µM – 1280 µM) dissolved in diethanolamine / MgCl2 buffer.  The fold enrichment in 
the final microvillus membrane pellet was calculated relative to the formation of p-
nitrophenol in the homogenate 1 sample.   
2.6.2. For determination of orientation of vesicles 
 Membrane vesicle samples were diluted to 1:10,000 with diethanolamine / MgCl2 
buffer with or without 0.2% Triton X-100 (detergent).  The alkaline phosphatase activity 
was measured as mentioned above.  The percentage of inside-out vesicles was calculated 
from the following equation. 
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Diethonolamine / MgCl2 buffer (pH 9.8) 
Diethonolamine / MgCl2 buffer consists of 1 M diethanolamine and 0.24 mM Magnesium 
chloride hexahydrate.   
Dissolve magnesium chloride in half the volume of water first and then add the 
diethanolamine and adjust the pH to 9.8 with HCl.  Store at 4°C.   
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2.7. Uptake Assay: Developmental Work and Final Protocol 
Since P-glycoprotein and ABCP are efflux transporters, membrane vesicles with 
inside-out orientation are useful in measuring the accumulation of radiolabeled substrate.  
The active uptake is determined by measuring the uptake in the presence and absence of 
ATP.  By measuring the time and osmotic dependent uptake we can distinguish between 
the actual uptake of the substrate across the membrane and non-specific binding of 
substrate to the membrane [84].  Vinblastine and mitoxantrone were used as model 
substrates for determining the activity of P-gp and ABCP, respectively.   
 
Membrane vesicles were diluted using the vesicle dilution buffer to a 
concentration of 2.5 mg/ml.  After dilution, the vesicles were syringed 10 times using a 
25-gauge needle.  Forty-five µL of transport buffer (with or without ATP) containing 
substrate and an ATP regenerating system was aliquoted into glass test tubes and 
maintained at 37°C.  The diluted vesicles were also placed in a water bath at 37°C.  
Following a 5 min pre-incubation, the reaction was initiated by addition of 10 µL of 
diluted vesicles to each tube at 30 sec intervals.  At the end of the incubation period (10 
min for vinblastine and 6 min for mitoxantrone), the reaction was quenched by addition 
of 3 ml of ice-cold quench buffer.  The quenched samples were immediately filtered 
through 0.45 µm nitrocellulose filters (Whatman), pre-soaked in 3% bovine serum 
albumin, using a Millipore 1225 Sampling Manifold.  The filters were then washed with 
an additional 3 ml of ice-cold quench buffer and then transferred with forceps to a 
scintillation vial.  Ten ml of Scintiverse® BD was added and the vials were shaken.  
They were allowed to sit for a few minutes before the samples were read using a 
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Beckman scintillation counter.  The cpm obtained from the instrument were then used in 
the following equation to calculate the uptake as pmol / mg of protein.  The ATP 
dependent uptake was the difference between the uptake in the presence and absence of 
ATP.   
 




×
×
=−
nmgofproteidedTotalCPMAd
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Buffer 2 
Buffer 2 consists of 10 mM Tris-HCl, pH 7.4 and 250 mM sucrose. 
 
Transport buffer 
Transport buffer consists of 10 mM creatine phosphate, 100 µg / ml creatine 
phosphokinase, 10 mM magnesium chloride hexahydrate and 4 mM ATP (added only in 
+ ATP transport buffer).  The volume was made up with buffer 2. 
 
For vinblastine uptake assay: 
20 nM [3H]-vinblastine (stock of 0.25 µCi / µL) + enough cold vinblastine (5 µM stock in 
buffer 2) to make a final concentration of 100 nM.   
 
For mitoxantrone uptake assay; 
50 nM [3H]-mitoxantrone (stock of 1 µCi / ml) + enough cold mitoxantrone (5 µM stock 
in buffer 2) to make a final concentration of 100 nM. 
 
Vesicle dilution buffer: 
Vesicle dilution buffer consists of 10 mM creatine phosphate, 100 µg / ml creatine 
phosphokinase and 10 mM magnesium chloride hexahydrate.  The volume was made up 
with buffer 2. 
 
Quench buffer: Ice-cold buffer 2 
 37
2.7.1. Time Dependent Uptake Assay 
 For determining the time course of the reaction, the membrane vesicles were 
incubated with vinblastine in transport buffer as outlined above and the reaction was 
quenched at 0, 1, 2, 4, 6, 8, 10, 15, 20, 30 and 60 min.  The uptake was measured in the 
presence and absence of ATP.   
 
2.7.2. Osmotic Dependent Uptake Assay 
 To determine whether the uptake was sensitive to osmolarity changes, increasing 
concentrations of sucrose were added to the transport buffer.  The transport buffer 
contained 250 mM, 333 mM, 500 mM and 1 M sucrose with rest of the additives 
remaining the same.  Vinblastine uptake was measured in the presence and absence of 
ATP for 10 min in triplicate.  The remainder of the procedure was followed as outlined 
above in the uptake protocol.   
 
2.7.3. Determination of type of filters and filter soaking media to block the 
non-specific binding 
 Two different types of filters, nitrocellulose (0.45 µm) and glass fiber filters (GF / 
F), were used with different types of soaking media: 10% fetal bovine serum, 3% bovine 
serum albumin, 5 µM unlabeled vinblastine (for 5 min and 1 h).  Also, 1 µM and 10 µM 
unlabeled vinblastine was used in the quench media to determine if it would decrease the 
non-specific binding of [3H]-vinblastine to the filters.   
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2.7.4. Inhibition studies 
 The uptake assay was carried out in the presence of inhibitors of P-gp and ABCP 
to assess the involvement of the transporters in the uptake of vinblastine and 
mitoxantrone, respectively.  Inhibition studies were also carried out to determine if either 
protein interfered with the transport of the model substrate of the other protein.   
The mitoxantrone uptake assay was carried out in presence of 10 µM 
fumitremorgin C (FTC), a selective inhibitor of ABCP [44] and 10 µM of verapamil, a 
known P-gp inhibitor.  Likewise, uptake of vinblastine was determined in presence of 
verapamil (10 µM and 100 µM) and 10 µM FTC.   
 
 
2.8. Immunoblotting Studies for Detection of P-gp and ABCP 
 Placental membrane vesicles were added to a volume of loading buffer to achieve 
a concentration of 2 µg/µL.  The broad range molecular weight markers (Bio-Rad) and 
samples were boiled for 10 min and 10 µg of protein (sample) was loaded on 15 well 7% 
NuPAGE Tris-acetate mini gels (Invitrogen).  Electrophoresis was carried out using a 
Surelock mini cell apparatus (Invitrogen) for 1 h 30 min at 130 volts.  Proteins were then 
transferred to a nitrocellulose membrane for 1 h 30 min at 30mV on ice.  The membrane 
was then stained with Ponceu S stain (Sigma) to confirm the transfer of the proteins and 
to mark the molecular weight markers.  The membrane was then blocked with 50 ml of 
blocking buffer and shaken for 1 h at room temperature.  The membrane was then probed 
with P-gp antibody C-219 or with ABCP antibody BXP-21 (Signet Laboratories).  The 
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primary antibody was diluted to 1:1000 in antibody dilution buffer and allowed to react 
with the membrane overnight at 4°C on a shaker.  Then next day the membrane was 
warmed to room temperature for 30 min prior to washing 4 times with wash buffer (10, 5, 
5 and 5 min).  A secondary antibody, horseradish peroxidase (HRP) linked sheep anti-
mouse antibody (1:5000, KPL Labs), was applied for 1 h at room temperature.  The 
membrane was again washed 4 times as earlier and the protein bands were detected using 
the enhanced chemiluminescence (ECL) detection reagents (Amersham Pharmacia 
Biotech).  The two ECL reagents (4 ml each) were mixed and poured over the membrane 
for 1 min.  The membrane was subsequently sandwiched between 2 transparency sheets 
and placed in a Hyperfilm cassette (Amersham Pharmacia Biotech).  The X-ray films 
were then exposed to the membrane for various time intervals and the film was developed 
using an X-ray film developer.  The relative amounts of P-gp and ABCP were determined 
by density measurements made using Optimas Imaging software (Media Cybernetics, 
Silverspring, MD) and reported as optical density (O.D.) values.   
 
 Though equal amounts of protein were loaded per lane, the data was normalized 
with actin protein to take into account if there were any differences in protein load.  The 
membranes which were probed for P-gp and ABCP were washed with wash buffer and 
stripped using stripping buffer.  The stripped membranes were then probed with anti-
actin antibody (1:200; SantaCruz) followed with (HRP) linked human anti-goat antibody 
(1:2000; SantaCruz).  The remainder of procedure was followed as outlined above.   
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Stocks of sample buffer (NP0007), running buffer (LA0041) and transfer buffer 
(NP0006) were purchased from Invitrogen and buffers were prepared according to 
manufacturer’s directions.  All the buffers were prepared fresh on the day of experiment.   
 
10X TBS: 1 pack of TBS (BupH Tris Buffererd Saline packs (Pierce); 25 mM Tris, 0.15 
M sodium chloride, pH 7.2 when pouch contents dissolved in a final volume of 500 ml 
dH2O) dissolved in 50 ml of distilled water.   
 
TBS 1X: 2 packs of TBS in 1 liter of distilled water. 
 
Blocking buffer: 5% milk in Tris-buffered saline (TBS)  
To 5 ml TBS 10X add 2.5 gm non-fat dry milk and q.s. to 50 ml with distilled water. 
 
Antibody dilution buffer: 1% milk in 0.5% Tween 20 and TBS 
To 20 ml of TBS 10X add 2 gm of non-fat dry milk and 0.1 ml of Tween 20 and then q.s. 
to 200 ml with distilled water. 
 
Wash buffer: 0.1%Tween 20 in TBS 
Add 1 ml Tween 20 to 1 liter of TBS 1X. 
 
Stripping buffer: 
Stripping buffer consists of 7 M guanidine HCl, 0.05 mM EDTA, 0.1 M potassium 
chloride, 20 mM of β-mercaptoethanol, 50 mM glycine and distilled water to make up the 
volume. 
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2.9. Preparation of Placental Microsomes 
 Placental microsomes were prepared according to the methods of Vaz et al. [85]  
Briefly, tissues were removed from the -80°C freezer and allowed to thaw on ice in 1% 
KCl.  All steps were carried out at 4°C (on ice) or in a refrigerated centrifuge.  After 
removal of the chorionic plate, the tissue was cut into small pieces and washed several 
times with 1% KCl to remove excess blood.  The tissue was then finely minced using 
scissors.  To this minced tissue, homogenization buffer was added (4 ml/gm of tissue).  
Aliquots of tissue were then disrupted with a Virtishear tissue homogenizer for 1 min and 
transferred to a Potter-Elvejehem vessel and homogenized by five passes with a pestle.  
The homogenized tissue suspension was then centrifuged in a refrigerated Sorvall RC 5B 
(Rotor = SA 600) in 50 ml tubes at 10,000 rpm at 4°C for 20 min.  The supernatant was 
transferred to clean ultracentrifuge tubes and centrifuged in a Beckman Coulter OptimaTM 
LE-80K Ultracentrifuge (Rotor = Ti 70.1) at 100,000 g and 4°C for 60 min.  The 
supernatant was discarded and wash buffer (same volume as homogenization buffer) was 
added to the pellet.  The pellets were resuspended using a glass stirring rod and 
centrifuged again for 60 min at 100,000 g as above.  The supernatant was discarded and 
the pellets were resuspended in storage buffer (1 ml per 5 gm of starting tissue), then 
transferred to a 5 ml Potter-Elvejehem tube and homogenized by 3 passes of a pestle.  
The suspended microsomes were then aliquoted in labeled microcentrifuge tubes and 
stored at -80°C.  The protein concentration was determined using BCA protein assay kit 
as described earlier.   
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 KP Stock Buffer (1 M) 
K2HPO4    190.71 g 
KH2PO4    21.78 g 
q.s. to 1 liter with distilled water. 
 
Homogenization Buffer (pH 7.5) 
Homogenization buffer consists of 0.15 M KCl and 0.25 M KP buffer 
The buffer was made up to volume with distilled water and pH was adjusted to 7.5 with 
H3PO4.  PMSF(1 mM) was added from 100mM stock in absolute ethanol just before use. 
 
 
Wash Buffer (pH 7.5) 
Wash buffer consists of 0.1 M sodium pyrophosphate and 1 mM EDTA (disodium salt, 
dihydrate).  The volume was made up with distilled water and pH was adjusted to 7.5.   
 
 
Microsomal Storage Buffer (pH 7.25) 
Microsomal storage buffer consists of 100 mM KP buffer, 1 mM EDTA (disodium salt, 
dihydrate), 20% glycerol, 1 mM dithiothreitol and 20 µM butylated hydroxytoluene.  The 
volume was made up with distilled water and pH was adjusted to 7.25 
 
 
 
2.10. Ethoxyresorufin-O-deethylation Assay for CYP1A1 
 7-ethoxyresorufin-O-deethylation (EROD) activity catalyzed by CYP1A was 
determined in placental microsomes according to the methods of Burke et al. [86] with 
slight modifications.  Briefly, a 1.25 ml incubation mixture contained Na-K phosphate 
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buffer (0.1 M, pH 7.6), 0.5 mg/ml of microsomal protein and 20 µM of 7-ethoxyresorufin 
(2 mM stock in DMSO).  Following a one minute pre-incubation at 37°C, 1 ml of the 
reaction mixture was transferred to a quartz cuvette and autozero was set on the 
spectrofluorometer.  The reaction was initiated by addition of 1 mM NADPH (freshly 
prepared 20 mM stock in water) and the cuvette was inverted to ensure thorough mixing. 
Relative fluorescence intensity was measured using a Shimadzu RF-5301 PC 
spectroflurometer with excitation and emission wavelengths of 530 nm and 585 nm 
respectively.  The spectrofluorometer was maintained at 37°C.  Relative fluorescence 
intensity was measured for 10 min to determine the linear range which was found to be 
0.5 min to 3 min at 37°C.  The amount of resorufin formed from 7-ethoxyresorufin was 
determined using a standard curve for resorufin and activity was calculated from the 
equation given below and reported as pmol / min / mg of protein.  
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Sodium Potassium Phosphate Buffer 
Sodium phosphate buffer consists of 0.1 M Na2HPO4, 0.1 M KH2PO4, 2.5 mM MgCl2 
and 0.1 M KCl.  Make up the volume with distilled water and adjust the pH to 7.6. 
 
 
 44
2.11. Cell Culture 
 The JAR and BeWo, placental choriocarcinoma cell lines was obtained from 
American Type Culture Collection (ATCC).  These cell lines were used to study the 
induction of placental P-gp after treatment with known inducers of P-gp.   
 
Cell Culture Media –  Bewo cell line 
To Ham’s F12K media add sodium bicarbonate to get 1.5 g/L and 10% of fetal bovine 
serum.  Mix all the above ingredients outside the cell culture hood and then filter 
aseptically.   
Store at 4°C till use 
 
Cell Culture Media – JAR cell line 
RPMI 1640 media with 2 mM L-glutamine was adjusted to contain 1.5 g/L sodium 
bicarbonate, 4.5 g/L of glucose and 10 mM of Hepes.  To this add 10% of fetal bovine 
serum.   
Mix all the above ingredients outside the cell culture hood and then filter aseptically.  To 
this sterile media add the following sterile products aseptically.   
1.0 mM of sodium pyruvate, 5 ml of Penicillin / streptomycin solution (10,000 units/ml 
of penicillin G sodium and 10,000 µg/ml of streptomycin sulfate in 0.85% saline). 
Mix well and store at 4°C till use.   
 
Starting a new culture 
The cell culture media was warmed at 37°C.  A frozen vial of cells was removed 
from the liquid nitrogen freezer and kept on ice.  The vial was rapidly thawed at 37°C 
(within 2 min) and 1 ml of the cell suspension was transferred to a 75 cm2 cell culture 
flask containing 20 ml of warmed cell culture media.  The flask was then stored in a 
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incubator at 37°C and 5% CO2.  The medium was changed every other day and cells were 
subcultured every 4-5 days at the ratio of 1:8 for BeWo cells and 1:15 for JAR cells.   
 
 
Subculturing procedure 
Cell culture media, phosphate buffered saline (PBS) and trypsin containing 0.01% 
EDTA (aliquoted as 5 ml) were warmed at 37°C.  The media from the flask was aspirated 
out and cells were washed with 10 ml of PBS twice.  After aspirating the PBS, 5 ml of 
trypsin was added and the flask was transferred to the incubator for 5 min.  After 5 min 
the flask was gently tapped to loosen the cells from the surface of the flask.  Fifteen ml of 
media was added and the cell suspension was pipetted up and down to obtain a single cell 
suspension.  The cells were then split at the ratio of 1:8 (BeWo cells) or 1:15 (Jar cells) 
into a new flask as well as 6 well plates which were used for induction studies.   
 
2.11.1. Induction studies 
 The cells were plated in 6 well culture plates.  At 50 % confluency of cells, the 
cells were treated with drugs dissolved in DMSO or appropriate solvent.  The JAR cells 
were treated with 10 µM rifampin, 10 µM clotriamazole, 0.1, 1, 5, 10 and 25 µM 3-
methyl cholanthrene (3-MC) dissolved in DMSO or 10 and 50 µM benzo-[a]-pyrene 
dissolved in acetone.  The cells were also treated with appropriate vehicle controls.  
BeWo cells were treated with 10 and 25 µM rifampin and DMSO as solvent control.  At 
the end of 72 h, the media was aspirated and cells were washed twice with PBS non-
aseptically.  The cells were then kept on ice and 300 µL of lysis buffer was added.  The 
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plate was shaken periodically for 10-15 min on ice.  With a help of a cell scraper or 
rubber policeman, the lysed cells were scraped and transferred to an appropriately labeled 
1.5 ml microcentrifuge tube.  The cell lysate was then sonicated on ice for 10 sec (x 3) 
using a sonicator tip.  The cell lysate was aliquoted and stored at -80°C.  Protein content 
was determined using the BCA assay kit as described earlier.  Immunoblotting studies (as 
outlined above) were carried out on these cell lysates to determine if P-gp was induced in 
these treated cells.   
 
Lysis buffer   
Lysis buffer consists of 50 mM Tris-HCl, pH 7.0, 1.0% Triton X-100, 1 mM PMSF (100 
mM stock in absolute ethanol), 10 µg/ml leupeptin and 20 µg/ml aprotinin. 
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CHAPTER – III 
3. EVALUATION OF P-GLYCOPROTEIN AND ABCP 
EXPRESSION AND FUNCTION IN HUMAN 
PLACENTAL TISSUE FROM SMOKERS AND 
NON-SMOKERS  
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3.1. Introduction 
 
P-glycoprotein (P-gp), encoded by the ABCB1 (MDR1; multidrug resistance) 
gene, is an efflux transporter that pumps xenobiotics out of cells, utilizing ATP as the 
energy source.  P-gp is present in various normal tissues [9] like intestine, liver and 
kidney where it plays an important role in absorption, distribution and excretion of drugs 
[87].  In addition, P-gp also plays a role in the transport of xenobiotics across the blood 
brain barrier, modulating their CNS effects [88].  Another tissue in which P-gp regulates 
xenobiotic transfer is the placenta. Studies in mdr knock-out mice have demonstrated that 
placental P-gp can affect the transfer of xenobiotics across the placental barrier [10;13], 
suggestive of a role in protecting the fetus from drugs ingested by the mother during 
pregnancy or environmental toxicants.   
 Polycyclic aromatic hydrocarbons (PAH) are primary constituents of cigarette 
smoke and can be classified as environmental toxicants. Cigarette smoking has been 
associated with adverse outcomes during pregnancy including changes in function and 
structure of the placenta.  Furthermore, maternal smoking has been associated with 
increased fetal morbidity and mortality.  Smoking and the associated PAHs can affect 
drug metabolizing enzymes and increase levels of cytochrome P450 1A1 (CYP1A1) in 
human placenta [62].  However, the effect of smoking on drug efflux transporters 
expressed in placenta is not known.  In-vitro studies using rat [76], mouse [77] and 
human hepatocytes [17], have demonstrated that P-gp mRNA was induced by 3-
methlycholanthrene (3-MC), a PAH.  In addition, the PAH benzo[a]pyrene, which is a 
substrate of CYP1A1, is also transported by P-gp [78].  Thus, analogous to CYP1A1 
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induction, there could possibly be induction of P-gp in placentas of women who smoke 
during pregnancy. Based on these lines of evidence, we hypothesized that smoking might 
increase P-gp levels in human placenta.   
In addition, we also studied the expression and function of ABCP which is a 
recently discovered protein belonging to the ABC superfamily of proteins.  ABCP [36], 
also known as MXR [38] or BCRP [37], is a 70 kDa protein encoded by ABCG2 and is 
also involved in the active efflux of drugs.  It is expressed at high levels in placenta, liver 
and small intestine and lower expression is seen in kidney, heart and brain [38;49].  
Studies in mdr knock-out mice have shown that there was increased placental transfer of 
topotecan in mdr knock-out mice in the presence of GF120918, an ABCP inhibitor, as 
compared to without GF120918 [51].  This suggests a protective role of ABCP, similar to 
P-gp, in the placenta.   
To study the effect of smoking on function and expression of both these proteins, 
placentas were collected from smokers and non-smokers and membrane vesicles isolated.  
In addition, since CYP1A1 activity is induced by smoking [62], CYP1A1 activity was 
also measured in human placental microsomes as a positive control for the effect of 
smoking.   
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3.2. Methods 
 
Materials.  [3H]-vinblastine (10.9 Ci/mmol) and [3H]-mitoxantrone (3 Ci/mmol) 
were purchased from Amersham Biosciences (Piscataway, NJ) and American 
Radiolabeled Chemicals (St. Louis, MO) respectively.  Verapamil, mitoxantrone, 
vinblastine, resorufin, 7-ethoxyresorufin, ATP, creatine phosphokinase, NADPH, EGTA, 
PMSF and bovine serum albumin were purchased from Sigma Chemical Co. (St. Louis, 
MO).  Creatine phosphate was purchased from Fluka (Switzerland).  Scintiverse ® BD, 
magnesium chloride and EDTA were purchased from Fisher Co. (Pittsburgh, PA).  
Fumitremorgin C (FTC) was a gift from Dr. Susan Bates (NIH).  All other chemicals 
were purchased from commercial sources and were of the highest purity available.   
 
Tissue Collection.  Human placental tissue was obtained under a protocol 
approved by the West Virginia University Institutional Review Board for the Protection 
of Human Research Subjects.  Placentas were obtained from ten smokers and ten non-
smokers who had given written informed consent prior to obstetric delivery.  Smoking 
status was assessed by patient interview.  Placentas were collected and processed 
immediately after delivery.  Two triangular wedges extending from center of the placenta 
to the placental margin were cut.  One piece was frozen at -80°C for later preparation of 
microsomes and the other piece was immediately processed to prepare the membrane 
vesicles.   
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Preparation of Microvillus Membrane Vesicles.  Microvillous membrane 
vesicles (MVM) were prepared according to the methods of Illsley et al. [79].  Briefly, 
the tissue was cut and washed in 0.9% NaCl.  The washed tissue was further minced 
finely and suspended in 3 volumes of buffer containing 10 mM Tris-Hepes (pH 7.0), 250 
mM sucrose, 5 mM EGTA, 5 mM EDTA and 1 mM PMSF (buffer 1).  This suspension 
was homogenized for 2 min and centrifuged at 10,000 g for 15 min.  The supernatant was 
collected and centrifuged at 47,500 g for 1 h.  The pellet was resuspended in buffer 1 and 
MgCl2 was added (12 mM final concentration).  The mixture was stirred on ice for 20 
min and centrifuged at 2500 g for 15 min. The supernatant was again centrifuged at 
47,500 g for 30 min to get the MVM pellet.  This pellet was washed and resuspended in 
buffer 2 (10 mM Tris-HCl (pH 7.4) and 250 mM sucrose) using a 25-gauge needle 
through which the suspension was passed ten times.  The vesicles were aliqouted and 
stored at –80°C.  Protein concentration was determined by the BCA assay kit (Pierce).  
The percentage of inside-out vesicles was determined by sialidase accessibility [81] [82] 
and membrane vesicles were found to be 18-20% inside-out.   
 
Uptake by Membrane Vesicles.  ATP dependent transport of the radiolabeled 
substrate into membrane vesicles was measured by filtration using a 12 channel sampling 
manifold (Millipore. Corp., Bedford, MA).  Transport buffer (45 µL) containing 10 mM 
Tris-HCl pH 7.4, 250 mM sucrose, 10 mM MgCl2, 20 nM [3H]-vinblastine (5000 cpm) or 
50 nM [3H]-mitoxantrone (1300 cpm) and enough amount of respective unlabeled drug to 
produce a final concentration of 100 nM and an ATP regenerating system consisting of 
10 mM phosphocreatine and 100 µg/ml creatine kinase were warmed at 37°C before 
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initiating the reaction.  Reactions were carried out in the presence or absence of 4 mM 
ATP.  The reaction was initiated by addition of 10 µL of vesicle aliqout (25 µg of 
protein) and quenched after 10 min (vinblastine) or 6 min (mitoxantrone) with the 
addition of 3 ml of ice-cold stop solution (10 mM Tris-HCl pH 7.4 and 250 mM sucrose).  
The quenched reaction mixture was filtered immediately through nitrocellulose filters 
(0.45 µm Whatman) presoaked in 3% BSA, and washed with an additional 3 ml of ice-
cold stop solution under light suction.  The filters were then placed in a scintillation vial, 
Scintiverse® BD scintillant added, and radioactivity measured by liquid scintillation 
counting.  ATP dependent uptake of radiolabeled substrate was calculated as the 
difference in the uptake of substrate measured in the presence and absence of ATP and 
reported as pmol / mg of protein.   
 
Immunoblotting for P-gp and ABCP.  Membrane vesicle protein (10 µg) was 
heated at 90°C for 10 min then loaded onto 7% Tris-acetate mini-gels (Invitrogen) and 
electrophoresed.  The proteins were then transferred to a nitrocellulose membrane after 
which the membrane was blocked in blocking buffer (5% non-fat dry milk in Tris 
buffered saline) for 1 h at room temperature and then incubated with C-219 P-gp 
antibody or BXP-21 ABCP antibody (1:1000, Signet Laboratories) overnight at 4°C.  The 
membrane was then washed with Tris buffered saline containing 0.1% Tween 20 (TTBS) 
and incubated with horseradish peroxidase linked sheep antimouse antibody (1:5000, 
KPL Labs) for 1 h at room temperature.  After washing with TTBS, the blots were 
developed with an enhanced chemiluminescence detection system (Amersham Pharmacia 
Biotech).  The relative amounts of P-gp and ABCP were determined by density 
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measurements made using Optimas Imaging software (Media Cybernetics, Silverspring, 
MD) and reported as optical density (O.D.) values.   
 
Measurement of CYP1A1 activity.  Placental microsomes were prepared 
according to established methods [85].  Ethoxyresorufin-O-deethylation (EROD) activity 
catalyzed by CYP1A1 was determined as described by Burke et al. [86] with slight 
modifications.  Briefly, 0.5 mg/ml of microsomal protein was incubated with 20 µM of 7-
ethoxyresorufin (2 mM stock in DMSO) and Na-K phosphate buffer (0.1 M, pH 7.6) in a 
total volume of 1.25 ml at 37°C for 1 min.  One ml of the reaction mixture was 
transferred to a cuvette and the reaction was initiated by addition of 1 mM NADPH.  
Relative fluorescence intensity was monitored for 4 min using a Shimadzu RF-5301PC 
spectroflurometer at 37°C and set at excitation and emission wavelengths of 530 nm and 
585 nm, respectively. The rate of formation of resorufin from 7-ethoxyresorufin was 
calculated from a standard curve for resorufin and activity reported as pmol / min / mg of 
protein.   
 
Statistical Analysis.  Statistical comparisons of P-gp, ABCP and CYP1A1 
activity as well as P-gp and ABCP expression between smokers and non-smokers were 
made using a one sided t test.  Statistical significance was set at p<0.05.   
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3.3. Results 
 
P-gp and ABCP expression in human placenta.  A 170 kDa P-gp protein was 
detected in all 20 samples of human placenta.  However, substantial inter-individual 
variability in P-gp expression among the samples was noted (Figure 3.1).  Statistical 
analysis showed that P-gp protein abundance was comparable between smokers and non-
smokers (Table 3.1).  Similarly, an ABCP protein band was detected at 70 kDa, as 
reported by others, and its expression also was comparable between smokers and non-
smokers (Table 3.1).   
 
Uptake of [3H]-vinblastine in membrane vesicles (P-gp activity).  ATP 
dependent transport of [3H]-vinblastine was observed in membrane vesicles isolated from 
human placenta.  This transport was also time dependent (data not shown).  To determine 
whether the transport was truly intravesicular or just due to increased binding to P-gp in 
the presence of ATP, the effect of osmolarity on the transport of vinblastine by P-gp was 
studied.  Figure 3.2 demonstrates that the transport observed was intravesicular as the 
uptake decreased with decreasing intravesicular volume resulting from increased 
osmolarity.   
 To determine if the vinblastine uptake was mediated by P-gp, uptake studies were 
carried out in the presence of verapamil, a known inhibitor of P-gp.  ATP dependent 
vinblastine uptake was inhibited 42 % by 10 µM and 71% by 100 µM verapamil (Figure 
3.3), confirming the involvement of P-gp in vinblastine uptake.   
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Table 3-1  Expression of P-gp and ABCP in placental vesicles 
Optical density values (mean ± S.D.) for P-gp and ABCP protein abundance in human 
placental tissue from smokers and non-smokers. 
 
Densitometric analysis 
(O.D.) 
Smokers 
(n = 10) 
Non-smokers 
(n = 10) 
P-gp expression 4.26 ± 1.30 3.88 ± 2.28 
ABCP expression 3.79 ± 1.71 2.81 ± 1.04 
 
O.D. = optical density 
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1       2       3       4       5      6       7       8       9      10    11     12 
?170 kDa 
Figure 3-1  Representative immunoblot of P-gp in placental vesicles 
Lanes 1, 3, 9, 11 and 12 are samples from smokers and lanes 2, 4, 5, 6, 7, 8 and 10 are 
samples from non-smokers.   
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Figure 3-2  Effect of osmolarity on ATP dependent uptake of [3H]-vinblastine in 
microvillus membrane vesicles.  
Placental vesicles (25 µg) were incubated for 10 min with [3H]-vinblastine in the 
presence or absence of ATP (4 mM) in transport buffer containing increasing 
concentrations of sucrose (250, 333, 500 and 1000 mM).  Data represent the difference 
between the ATP dependent and independent uptake determined in triplicate samples.  
The coefficient of variation was less than 15% for each triplicate determination.   
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Figure 3-3  Effect of verapamil on ATP dependent uptake of vinblastine in 
microvillus membrane vesicles 
Data represents the ATP dependent transport of vinblastine in absence (control) and 
presence of verapamil (VER 10 µM and VER 100 µM).  Mean of triplicate 
determinations with coefficient of variation less than 15% for all sets.   
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Figure 3-4  Correlation of P-gp activity with P-gp expression 
On correlating P-gp activity with P-gp expression a positive correlation was seen with an 
r2 = 0.45. 
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Placental P-gp activity, measured as the uptake of vinblastine, was not statistically 
different (p>0.05) in smokers and non-smokers (Table 3.2).  With respect to the 
correlation of P-gp expression and activity, a positive correlation, r2 = 0.45 was obtained 
(Figure 3.4).   
 
Uptake of [3H]-mitoxantrone in membrane vesicles (ABCP activity).  ATP 
dependent transport of mitoxantrone was observed in membrane vesicles.  To determine 
if this transport was mediated by ABCP, mitoxantrone uptake was measured in the 
presence of fumitremorgin C, a selective inhibitor of ABCP as well as verapamil, an 
inhibitor of P-gp.  In the presence of 10 µM fumitremorgin C, a 65% inhibition of ATP 
dependent mitoxantrone transport was observed whereas 10 µM verapamil had minimal 
effect (Figure 3.5). Placental ABCP activity, measured as the uptake of mitoxantrone, 
was not statistically different (p>0.05) between smokers and non-smokers (Table 3.2).  
With respect to the correlation of ABCP expression and activity, a positive correlation, r2 
= 0.25 was obtained (Figure 3.6).  However, on exclusion of one data point as an outlier a 
better correlation with r2 = 0.74 (Figure 3.6) was obtained.   
ABCP is a half transporter and is thought to require dimerization to be active [89].  
It has been demonstrated that in the absence of reducing agent, ABCP migrates as 140 
kDa protein on electrophoretic gels [39].  We observed similar results on blots where 
ABCP migrated as a 140 kDa protein under non-reducing conditions (in the absence of 
dithiothreitol, DTT) and as a 70 kDa protein under reducing conditions (in the presence 
of DTT) (Figure 3.7).  This suggests that ABCP exists as a dimer in non-reducing 
conditions and as a monomer under reducing conditions.  In addition, we were also able 
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to demonstrate for the first time that there was decreased transport of mitoxantrone by 
ABCP in presence of 1 mM DTT as compared to without DTT (Figure 3.8).  Thus, in 
presence of DTT, ABCP appears to be present as a monomer and loses its ability to 
transport substrates.  These results taken together confirm that ABCP requires 
dimerization to be functional.   
 
Ethoxyresorufin O-deethylation (EROD) in placental microsomes (CYP1A1 
activity).  As a positive control for the effects of smoking, we measured CYP1A1 
function using the EROD assay.  CYP1A1 activity was highly induced in smokers, 
however, we were only able to measure this activity in 2 out of 10 microsomal samples 
prepared from placentas of non-smokers.  Table 3.2 shows the activity seen in each group 
and the range of values obtained.   
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Figure 3-5  Effect of an ABCP inhibitor (FTC) and a P-gp inhibitor (VER) on the 
uptake of mitoxantrone in microvillus membrane vesicles 
Data represent ATP dependent uptake of mitoxantrone.  Fumitremorgin C (FTC) 
inhibited mitoxantrone uptake by 65 % whereas verapamil (VER) had minimal effect on 
mitoxantrone transport suggesting that mitoxantrone transport is predominantly mediated 
by ABCP.  Mean of triplicate determinations with coefficient of variation less than 15% 
for all sets.   
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Table 3-2  Functional activity of P-gp, ABCP and CYP1A1 
Functional activity (mean ± SD) of P-gp and ABCP measured as uptake of vinblastine 
and mitoxantrone, respectively, in microvillus membrane vesicles.  CYP1A1 activity 
(mean ± SD) measured as ethoxyresorufin -O-deethylation in placental microsomes.   
 
Parameter (units) 
Smokers 
(n = 10) 
Non-smokers 
(n = 10) 
P-gp mediated vesicular uptake of vinblastine  
(pmol / mg of protein) 
2.25 ± 1.12 1.72 ± 0.67 
ABCP mediated vesicular uptake of mitoxantrone  
(pmol / mg of protein) 
6.25 ± 1.55 5.53 ± 2.09 
CYP1A1 activity in placental microsomes  
(pmol / min / mg of protein) 
3.61 ± 2.96 
0.56  
(0.19 , 0.93) * 
 
* Measurable values, 8 of the 10 samples were below the limit of detection.   
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Figure 3-6  Correlation of ABCP activity with ABCP expression 
The dashed line represents the regression line with all the data points and has a r2 = 0.25 
whereas the solid line represents the regression line with all the data points except one 
which is shown in a box and has a r2 = 0.74. 
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Figure 3-7  Immunoblot expression of ABCP in the presence and absence of 
reducing conditions 
Electrophoresis was carried out under reducing conditions [presence of 1 mM DTT] (lane 
1, 3 and 5) and under non-reducing conditions [absence of 1 mM DTT] (lane 2, 4 and 6).  
Band at 140 kDa is suggestive of the presence of a dimeric form of ABCP whereas the 
band at 70 kDa is suggestive of a monomeric form.   
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Figure 3-8  Effect of 1 mM dithiothreitol (DTT) on ATP dependent uptake of 
mitoxantrone by ABCP in placental vesicles from two subjects (PT-20 and PT-22) 
Uptake of [3H]-mitoxantrone in placental vesicles (25 µg) in the absence (dark bars) and 
presence (light bars) of 1 mM DTT.  Each bar represents the difference in uptake in 
presence and absence of ATP (4 mM) carried out in triplicate and coefficient of variation 
was less than 15% for all sets.   
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3.4. Discussion 
 PAHs, which are the principal constituents of cigarette smoke, have been shown 
to induce drug-metabolizing enzymes such as CYP1A1 in human placenta.  It has been 
reported that PAHs such as 3-MC can induce the levels of P-gp mRNA in rat [76], mouse 
[77] and human hepatocytes [17].  However, the effect of smoking on placental drug 
efflux transporters, such as P-gp and ABCP, is not known.  To this end, we studied the 
function and expression of placental P-gp and ABCP and their regulation by smoking in 
placentas from smokers and non-smokers.   
Vinblastine was used as a model substrate of P-gp function in placental vesicles.  
To confirm that measured radioactivity on the filters was due to intravesicular transport 
and not just increased binding to vesicles, experiments in which increasing concentrations 
of sucrose were added to the transport buffer were conducted (Figure 3.2).  Increased 
osmolarity of the medium should decrease the intravesicular volume and lead to 
decreased uptake in vesicles if intravesicular transport is occurring [84].  As seen in 
Figure 3.2, the uptake of vinblastine decreased as the osmolarity of the transport buffer 
increased, demonstrating that the observed ATP dependent transport was at least partly 
intravesicular and not due to increased binding of vinblastine to P-gp.  Additional 
confirmation of the involvement of P-gp in this active transport process was obtained by 
using verapamil, an established inhibitor of P-gp.  Verapamil 10 µM and 100 µM 
inhibited ATP dependent vinblastine uptake by 42% and 71%, respectively (Figure 3.3).  
That the process was osmotically sensitive and inhibited by a known P-gp inhibitor 
strongly suggests that the ATP dependent transport of vinblastine was intravesicular and 
carried out by P-gp.   
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 In addition to P-gp, ABCP also has been reported to be present at the apical 
surface of placenta.  To the best of our knowledge, there are no reports of functional 
studies of ABCP in human placenta.  Mitoxantrone, a known substrate for ABCP, was 
used to measure ABCP function in the microvillus membrane vesicles.  To verify the 
involvement of ABCP in mitoxantrone transport, uptake experiments were performed in 
the presence of fumitremorgin C (10 µM), a selective inhibitor of ABCP [44], and 
verapamil (10 µM), a P-gp inhibitor.  As shown in Figure 3.4, fumitremorgin C inhibited 
mitoxantrone uptake by 65 % whereas verapamil exhibited minimal effect.  Since 
verapamil exhibited a minimal effect on mitoxantrone uptake, suggests that the uptake of 
mitoxantrone was primarily mediated by ABCP and not by P-gp.   
 ABCP is a half transporter and has 6 transmembrane domains and only one ATP 
binding site, unlike P-gp which is a full transporter and has twelve transmembrane 
domains and two ATP binding sites [14].  As ABCP is a half transporter, it is assumed to 
require dimerization to be a functional protein [89].  In its monomeric form, ABCP 
migrates as a 70 kDa protein.  However, under non-reducing conditions ABCP migrates 
as a 140 kDa protein, suggesting it forms a dimer [39].  To confirm this dimerization, 
placental vesicle samples were electrophoresed under reducing (in the presence of DTT) 
and non-reducing conditions (in the absence of DTT) (Figure 3.5).  Under the non-
reducing conditions a large band was observed at 140 kDa, whereas this band was 
completely absent when samples were electrophoresed under reducing conditions, 
wherein it migrated as a 70 kDa protein.  The minimal expression of 70 kDa protein seen 
under non-reducing conditions could be due to some ABCP monomers that had not 
dimerized.  To confirm that dimerization of ABCP is necessary for functionality, we 
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performed mitoxantrone uptake studies in the presence and absence of 1 mM DTT 
(Figure 3.6).  As DTT is a reducing agent, it should cleave the dimer and thus decrease 
the functional activity of ABCP.  An approximately 65% reduction in mitoxantrone 
uptake was noted in the presence of DTT as compared to the absence of DTT.  These 
results suggest that ABCP dimerization is required for functionality.  Since no dimer was 
detected in the immunoblotting studies in the presence of DTT (reducing conditions), the 
small amount of mitoxantrone transport noted in the presence of 1 mM DTT was most 
likely due to the binding of mitoxantrone to ABCP in presence of ATP.   
Though substantial expression of P-gp and ABCP protein in placental vesicles 
was noted, no statistical differences were noted in expression levels between smokers and 
non-smokers (Table 3.1). Likewise, no statistical difference was noted in P-gp and ABCP 
functional activity between these two groups (Table 3.2), however, statistical power was 
low.  To achieve a power of 0.8 at p<0.05, it was calculated that a sample size of 26 
subjects per group would be required to meet these statistical levels for ABCP expression 
and substantially higher numbers of samples for P-gp expression and activity and for 
ABCP activity.  
As mentioned above, substantial inter-individual variability was seen in the 
expression and activity of P-gp and ABCP in human placental samples (Table 3.1 and 
3.2).  Induction of the ABCB1 gene by 3-MC and TCDD in human hepatocytes has been 
reported by Schuetz et al. [17].  Primary human hepatocytes from 15 individuals were 
treated with 3-MC and TCDD, from which only 62% and 55%, respectively, of the 
primary hepatocyte cultures showed induction of the ABCB1 gene, suggesting that this 
inducibility was polymorphic [17].  Genotyping studies have reported a SNP at C3435T 
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in exon 26 and subjects having the T/T allele exhibited much lower expression and 
activity of P-gp measured in-vivo, suggesting a correlation between the genotype and 
phenotype [33;34].  However, other researchers have reported that individuals with the 
T/T allele exhibit higher expression of P-gp and thus higher activity [35].  Thus, the 
effects of genetic polymorphisms with respect to the direction of change in P-gp 
expression and activity are still unclear.  These types of polymorphisms may in part, 
explain the substantial inter-individual variability in P-gp expression and activity noted in 
the present study.  Mutations in the amino acid at position 482 in ABCP overexpressing 
cells lines have also been reported, resulting in an alteration in substrate specificity of 
ABCP.  The wild type ABCP has arginine at position 482, which is replaced by threonine 
or glycine in mutated cells [43;53].  Whether these mutations exist in normal human 
tissues and change the expression and function of ABCP is not yet known.  To this end, 
we have begun studies to genotype the samples used in our study for correlation of 
genotype, phenotype and smoking status for both P-gp and ABCP.   
 To assure that maternal smoking was resulting in alterations in placental 
biochemical processes, measurement of CYP1A1 activity in placental microsomes was 
used as a positive control.  CYP1A1 activity was substantially greater in smokers as 
compared to non-smokers (Table 3.2).  Since smoking induced CYP1A1 activity but not 
P-gp or ABCP activity, the lack of effect appears not to be due to insufficient smoking 
activity necessary to induce biochemical processes such as P-gp or ABCP activity.   
 In conclusion, we were able to measure P-gp and ABCP expression and activity in 
placental membrane vesicles.  This constitutes the first report of functional studies on 
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ABCP in human placenta. However, it appears that smoking does not induce P-gp or 
ABCP activity or expression in human placenta.   
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CHAPTER – IV 
4. INDUCTION OF P-GLYCOPROTEIN AND CYP3A 
ACTIVITIES IN LS174T CELLS  
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P-gp can affect drug bioavailability as it plays a role in absorption, distribution 
and elimination.  Induction of P-gp leads to decreased absorption and increased 
elimination of drug substances and can play a role in drug-drug interactions.  Such 
interactions become extremely important for drugs that are P-gp substrates and have 
narrow therapeutic indices.  Our laboratory was interested in studying the induction of P-
gp by various xenobiotics.  At the same time, I was offered an opportunity to do a 
summer internship at Pharmacia Corp., Kalamazoo, MI, under the direction of Dr. Joseph 
Ware.  As a part of my summer internship, I worked on a project to evaluate LS174T 
cells as a model cell line to study the induction of P-gp and CYP3A4 simultaneously.   
 P-gp and CYP3A4 have a number of overlapping substrates and are co-localized 
in various tissues such as intestine, liver and kidney.  Common substrates are pumped 
back into the gut lumen by P-gp and metabolized by intestinal CYP3A4; thus, P-gp and 
CYP3A4 act additively to decrease the oral bioavailability of several xenobiotics.  In 
addition, both proteins are known to be coordinately upregulated.  To this end, 
development of a common system for studying both P-gp and CYP3A4 induction 
simultaneously could prove beneficial to the drug discovery process.   
 LS174T, a colon carcinoma cell line, has been used as an intestinal model.  It has 
been shown that in these cells the ABCB1 gene is inducible by rifampin.  There are 
reports of increased expression of P-gp in these cells, however, whether CYP3A4 is also 
induced in these cells has not been studied.  Given that both of these proteins have 
common inducers and are induced in intestinal tissue, the LS174T cell line seemed ideal 
for studying the simultaneous induction of P-gp and CYP3A4.   
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 The pregnane X-receptor (PXR) is a nuclear hormone receptor and is a key 
regulator of CYP3A4 induction.  Recently, its involvement in the regulation of the 
ABCB1 gene has also been noted.  PXR binding element is present in the upstream region 
of ABCB1 gene in LS174T cells.  At Pharmacia, Dr. Rich Voorman and Evan Smith use a 
reporter gene assay to screen compounds for their ability to activate PXR.  Since PXR is 
identified as a key regulator in the induction of P-gp and CYP3A4, the reporter gene 
assay results can be used for prediction of induction of P-gp and CYP3A4.  Our second 
purpose was to determine how data from the PXR reporter gene assay would correlate 
with results from induction studies in LS174T cells.  Thus a collaboration with Dr. Rich 
Voorman and Evan Smith was formed to evaluate the correlation of these results. 
Compounds which were poor, intermediate and strong activators of PXR were selected 
and their ability to induce P-gp in LS174T cells was compared and correlated to their 
ability to activate PXR in a reporter gene assay.   
The following chapter describes the experimental procedures used in these 
studies, their results and a discussion of the findings.  I would like to thank Dr. Rich 
Voorman and Evan Smith for sharing the PXR reporter gene assay data that is presented 
in the next chapter with me.   
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4.1. Introduction 
 
Prediction of drug-drug interactions early in the development of new drugs is 
beneficial in the process of drug discovery.  Induction of drug metabolizing enzymes and 
transporters that govern the absorption, distribution, metabolism and excretion of drugs is 
one cause of drug-drug interactions [22;90].   
The ABCB1 (MDR1) gene encodes for P-glycoprotein (P-gp), an ATP dependent 
integral transmembrane protein which acts as an efflux transporter.  It pumps xenobiotics 
out of cells and decreases their intracellular concentrations [4].  It is expressed in various 
tissues including intestine, liver, kidney, brain and placenta [87] wherein it plays a role in 
absorption, distribution and excretion of xenobiotics. 
Cytochrome P450 3A4 (CYP3A4) is an important drug metabolizing enzyme 
constituting about 70% of intestinal and 30% of the hepatic P450 metabolizing enzymes 
present.  It is responsible for metabolism of more than half of the drugs on the market 
[91;92]. Induction by a variety of chemicals augments the metabolism and clearance of 
co-administered drugs which are CYP3A4 substrates and can lead to alteration of their 
therapeutic efficacy [93;94].  Because of this, it is desirable to screen compounds for their 
ability to induce CYP3A.   
P-gp has broad substrate specificity with many compounds also being CYP3A4 
substrates [16].  Both proteins are expressed in several common tissues [95] and can 
additively affect the bioavailability of certain drugs [96;97].  Moreover, it has also been 
shown that both proteins are coordinately upregulated in colon carcinoma cells when 
exposed to common inducing agents [16].  Therefore, in addition to screening for 
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inducibility of CYP3A, compounds should also be screened for their ability to induce P-
gp.  In addition, the functional activity of these induced proteins is critical.   
Induction of CYP3A by different agents has been studied in animals [18], 
hepatocytes [98;99] and cell lines [16].  However, only recently has the molecular 
mechanism of induction been known.  Pregnane xenobiotic receptor (PXR), a nuclear 
hormone receptor, has been found to be responsible for drug induced expression of 
CYP3A4 [100;101].  PXR has also been implicated in the induction of P-gp [24].  A PXR 
response element to which PXR can bind was found in the 5’ upstream region of the 
ABCB1 gene [27].  As CYP3A4 and P-gp both depend on PXR for the control of 
expression, it is important to assess whether induction by various agents is common to 
each protein as well.  The colon carcinoma cell line LS174T has been shown to possess 
the ABCB1 gene which can be induced [27].  In the present work, this cell line was used 
to develop a model for simultaneous assessment of drug candidates for their ability to 
induce P-gp and CYP3A4 activity.  To further support the involvement of PXR in 
induction of ABCB1, the ability of various drugs to activate PXR was compared and 
correlated with their ability to induce P-gp.   
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4.2. Methods 
 
 Materials.  [3H]-vinblastine was purchased from Amersham Biosciences, 
(Piscataway, NJ).  Cyclosporin A was purchased from Fluka (Switzerland).  The 
chemicals with PNU number were synthesized by Pharmacia Corp. (Kalamazoo, MI).  
All other chemicals were purchased from commercial sources and were of the highest 
purity available.   
 
Cell Culture.  The colon carcinoma cell line LS174T was obtained from the 
American Type Culture Collection.  The cells were maintained in Minimum Essential 
Media supplemented with 10% fetal bovine serum, 0.1mM nonessential amino acids, 
sodium pyruvate and glutamine (Invitrogen).  The medium was changed every 3 days and 
the cells were subcultured at the ratio of 1:3 to 1:5.  In a 6 well culture plate at 50% 
confluence, cells were treated with drugs dissolved in DMSO (0.1% final concentration).  
0.1% DMSO was used as solvent control in cells not treated with drugs.  Treatment with 
drugs was continued for 72 hours or the indicated time, after which the cells were washed 
twice with phosphate buffered saline and then lysed with lysis buffer (50mM Tris, pH 
7.0, 1.0% Triton X-100, 1 Protease Minitab (Boehringer Ingelheim) /10mL).  The cell 
lysate was stored at -80°C.  Protein content was determined using the BCA protein assay 
kit (Pierce).   
 
Western Blot Analysis.  Cell lysates (10µg) were loaded on 7% Tris-acetate 
mini-gels (Invitrogen) and electrophoresed.  The proteins were transferred to a 
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nitrocellulose membrane and stained with Ponceu S solution (Sigma) to confirm transfer.  
The membrane was blocked in blocking buffer (5% non-fat dry milk in Tris buffered 
saline) for 1 h at room temperature and then incubated with C-219 P-gp antibody 
(1:1000, Signet laboratories) overnight at 4°C.  The membrane was then washed with 
Tris buffered saline containing 0.1% Tween 20 (TTBS) and incubated with horseradish 
peroxidase linked sheep antimouse antibody (1:5000, KPL laborartories) for 1 h at room 
temperature.  After washing with TTBS, the blots were developed with enhanced 
chemiluminescence detection system (Amersham Pharmacia Biotech).  The relative 
amounts of P-gp were determined by densitometric analysis after scanning the blot using 
a Bio-Rad densitometer.   
 
Flow Cytometry.  Cell suspensions (100 µl) at 1-2 x 106 cells/ml were incubated 
with either control (γ2a, Becton Dickinson) or anti-P-gp (MRK-16, Kayima Biomedical 
Co.) monoclonal antibodies (20 µl at 50 µg/ml) for 1 h at room temperature.  After 
centrifugation and removal of supernate, fluorescent-goat anti-mouse IgG (100 µl at 1/50 
dilution) was added and incubated for 45 min at room temperature, followed by 
centrifugation and resuspension in 200 µl sheath buffer (Becton Dickinson).  Samples 
were analyzed in a FACScan (Becton Dickinson) flow cytometer by gating on cells using 
forward (FSC) and side (SSC) scatter parameters and measuring fluorescence at 530 nm 
(FL1 channel). 
 
Uptake of [3H]-Vinblastine.  Cells were grown at high density in 24 well plates 
with 12 wells treated with 10 µM rifampin and the other 12 wells with 0.1% DMSO 
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solvent control.  At the end of 72 h the cells were washed twice with PBS at 37°C with 
mixing.  The control wells and rifampin treated wells were pretreated with 5 µM 
cyclosporin A (n = 6) and vehicle (n = 6) for 30 min at 37°C.  [3H]-vinblastine (0.25 
µCi/mL) was added and incubated for 1 h at 37°C with mixing.  At the end of 1 h the 
remaining solution was aspirated and the cells were rinsed twice with ice-cold PBS.  The 
cells were then dissolved in Solvable TM for 30 min at 37°C and transferred to a 
scintillation vial to measure the amount of cell associated radioactivity.   
 
Measurement of 1’-hydroxy midazolam.  The LS174T cells were washed twice 
with PBS and then incubated with 10 µM midazolam at 37°C for 1 h on a slow shaker.  
At the end of 1 h the reaction was stopped with quenching solution (5 µg/ml of 
carbamazepine (internal standard) in methanol and 3% formic acid).  The contents of 
each well were transferred to tubes and centrifuged (14000 rpm).  The supernate was 
analyzed for 1’-hydroxy midazolam using LC-MS analysis.  LC/MS was performed in 
positive ion scan mode on a Finnigan-MAT TSQ 7000, and by gradient reverse-phase 
chromatography (0.1% formic acid 95% to 0% in ACN over 20 min) on a Zorbax C18, 
150 x 2.1 mM i.d. reverse-phase column (0.3 ml/min).  Extracted ion chromatograms of 
carbamazepine (MH+ m/z 237) and hydroxy-midazolam (MH+ m/z 342) were obtained 
and used to determine peak area ratios (metabolite-of-interest / carbamazepine).   
 
PXR reporter gene assay:  HUH7 cells, maintained in RPMI Medium 1640 
(Invitrogen Corporation, Carlsbad, CA) supplemented with 10% heat-inactivated FBS 
(Invitrogen), 100 units/mL penicillin G (Invitrogen) and 100 µg/mL streptomycin sulfate 
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(Invitrogen), were plated at a density of 50,000 cells/cm2 growth surface area in 150 mm 
x 25 mm tissue culture dishes.  After eight hours, cells were transfected with 5.8 µg/dish 
of receptor expression plasmid and 23.4 µg/dish of reporter plasmid using Lipofectamine 
2000 (Invitrogen) essentially according to the manufacturer’s instructions.  Eighteen 
hours after transfection, cells were detached and diluted to 50,000 cells/mL with reduced 
serum medium (RPMI Medium 1640 supplemented with 1% FBS).  The diluted cell 
suspension was added to 96-well assay plates (200 µL/well) containing 1 µL samples of 
test compounds dissolved in DMSO.  Cells were incubated in the presence of test 
compounds for 24 hours before detection of luciferase activity using Sleady-Glo 
luciferase detection reagent (Promega).  Fold induction values were calculated by 
dividing the luminescence response for the test well of a given compound with the 
average luminescence response of the four DMSO control wells on the same plate. 
 
Statistical Analysis.  Unistat® version 5.0 was used for comparison of the two 
groups.  Correlations between groups were measured by Pearson’s correlation 
comparisons and statistical significance was set at p<0.05.   
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4.3. Results 
 
P-gp expression and function in LS174T cells.  Rifampin, a prototypical 
inducer of P-gp expression was used to characterize the induction of P-gp expression in 
LS174T cells. Immmunoblotting results demonstrated that induction by rifampin was 
dose (Figure 4.1) and time dependent (data not shown).  Based on these results, a dose of 
10 µM and 72 h time exposure were used in all further experiments.  In addition to 
rifampin, reserpine also induced P-gp expression (data not shown).  To determine the 
surface expression of P-gp in LS174T cells, flow cytometry measurements were carried 
out using MRK-16 anti P-gp antibody that recognizes the external epitope of P-gp.  
Vehicle (DMSO) and rifampin / reserpine treated cells were analyzed for their binding to 
control and MRK –16 antibody.  The fluroscence intensity was 3.5 and 4.0 fold higher in 
rifampin and reserpine treated cells respectively as compared to vehicle control treated 
cells (Figure 4.2).  This suggests that the induced protein is present at the cell surface of 
the cells.  To determine if the induced protein was functionally active, cellular uptake of 
[3H]-vinblastine was measured in the presence and absence of cyclosporin A (CsA, 5 
µM).  As seen in Figure 4.3, [3H]-vinblastine uptake was significantly lower (p<0.05) in 
rifampin treated cells as compared to vehicle control cells.  Uptake in the CsA treated 
control cells was significantly higher (p<0.05) than in control cells without CsA 
suggesting that baseline P-gp activity was inhibited by CsA.  Uptake of [3H]-vinblastine 
in rifampin treated cells also was higher in the presence of CsA than in the absence of 
CsA, however, this increase was not statistically significant.   
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Figure 4-1  Dose dependent induction of immunoreactive P-glycoprotein after 
rifampin treatment 
Cells at 50% confluency were treated with vehicle (DMSO) or 0.1, 1, 5, 10 and 25 µM of 
rifampin for 72 hrs.  At the end of 72 hrs the cell lysate was analyzed for P-gp expression 
by immunoblot analysis.   
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Figure 4-2  Determination of surface expression of P-gp in LS174T cells after 
treatment with rifampin and reserpine for 72 hours 
Anti-P-gp antibody (MRK-16) and control antibody (γ2) were incubated with solvent 
control (DMSO), drug treated cells (rifampin, Rif; reserpine, Res) and blank cells 
(without solvent or drug treatment).  After washing, the cells were incubated with 
fluorescent-labeled secondary antibody.  Samples were analyzed for fluorescence 
intensity at 530 nm in a flow cytometer.   
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Figure 4-3  Uptake of vinblastine in control and rifampin treated cells in the 
presence and absence of 5 µM cyclosporin A (CsA) 
Bars represent the means ± std.dev (n = 6).  Cells were treated with either DMSO (dark 
bars) or 10 µM rifampin (hatched bars) for 72 h.   
* p<0.05 as compared to vehicle control.  Reduction in uptake due to the induction of P-
gp by rifampin.   
** p<0.05 as compared to vehicle control.  Enhanced uptake due to the inhibition of P-gp 
by cyclosporin A (+ CsA) 
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CYP3A4 activity in LS174T cells after rifampin treatment.  Metabolism of 
midazolam to 1’-hydroxy midazolam (1’-OH MDZ) was used to measure CYP3A 
activity.  Formation of 1’-OH MDZ was found to be four times higher in rifampin treated 
cells as opposed to control cells (Figure 4.4).  Additionally, 1’-OH MDZ formation was 
inhibited by 10 µM ketoconazole, a CYP3A inhibitor, Figure 4.4.   
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Figure 4-4  Induction of CYP3A activity after 10 µM rifampin treatment.   
Formation of 1’-hydroxy midazolam was measured in control and rifampin (Rif) treated 
cells after treatment for 72 hrs.  The metabolite production was completely inhibited in 
presence of 10 µM ketoconazole (Ket) in both the control and rif treated cells.   
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Correlation of PXR activation and P-gp induction.  A total of 18 compounds, 
with known affinity for PXR, were tested for their ability to induce P-gp.  Compounds 
with high, intermediate and low affinity for PXR were selected and LS174T cells were 
treated with 10 µM of drug (except for hyperforin which was tested at 1 µM) in DMSO 
for 72 h.  P-gp expression was measured by immunoblotting and densitometric values 
were determined after scanning the blots.  Fold change was calculated with respect to 
DMSO control.  In Figure 4.5, the fold change in activation of PXR and expression of P-
gp is plotted for each of the compounds tested. Of the 18 compounds tested, rifampin, 
PNU-721, PNU-444, PNU-690 and SR12813 were strong activators of PXR as well as 
greatly induced P-gp expression.  Taxol, verapamil and PNU 352 strongly induced P-gp 
expression but moderately activated PXR.  On the other hand hyperforin strongly 
activated PXR but had very little inducing effect on P-gp expression.  Similarly, 
troglitazone was a moderate PXR activator but failed to increase P-gp expression.  Lastly 
phenytoin and delavirdine resulted in a moderate increase in P-gp expression but failed to 
activate PXR.  Ibuprofen and dexamethasone did not activate PXR or increase P-gp 
expression. The ability of the tested compounds to induce P-gp and activate PXR was 
rank ordered and although the rank order differed for P-gp induction and PXR activation, 
a positive correlation coefficient of 0.53 (Figure 4.6) was noted which was statistically 
significant (p<0.05).   
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Figure 4-5  Comparison of PXR Activation and P-gp Induction by Various Agents 
LS174T cells were treated with 10 µM of each compound (1 µM hyperforin) for 72 hrs.  
At the end of 72 hrs, cells were lysed and P-gp protein abundance was measured by 
immunoblotting analysis.  Blots were scanned and densitometric values were calculated.  
P-gp induction is reported as the fold change over the vehicle control.  Likewise, for the 
PXR reporter gene assay, data are reported as the fold change over vehicle control.   
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Figure 4-6  Correlation between the rank order for PXR Activation and Induction 
of P-gp expression 
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4.4. Discussion 
 
The present study demonstrates that LS174T cells can be used as a model cell line 
to screen for drugs that can induce P-gp and/or CYP3A.  By using a model inducer, 
rifampin, we have shown increased expression of P-gp in LS147T cells that was dose 
(Figure 4.1) and time dependent.  Schuetz et al. [16] have also shown increased 
expression of P-gp and CYP3A4 by immunoblot analysis to be dose dependent in LS180 
cells.  We were not able to detect CYP3A4 protein by immunoblotting in these cells 
before or after treatment with rifampin.  However, CYP3A activity was induced in a dose 
dependent manner following 72 h of rifampin treatment (data not shown).  The inability 
to detect protein by immunoblotting was most likely due to the relative insensitivity of 
western blotting as compared to activity measurements of formation of 1’-OH MDZ.  
CYP3A activity was completely inhibited in the presence of 10 µM ketoconazole, an 
inhibitior of CYP3A (Figure 4.4).   
Midazolam is a substrate for all CYP3A isoforms (CYP3A4, 5 and 7), however, 
the metabolic capabilities differ between the isoforms with CYP3A4 being the most 
active or equal to CYP3A5 and CYP3A7 having lower metabolic capacity [102].  
CYP3A5 is not induced by rifampin in human hepatocytes, colon carcinoma cell lines 
[16] or in human lymphocytes [103].  Moreover, the PXR binding domain is absent in the 
5’ promoter region of the CYP3A5 gene [104].  CYP3A7 is mostly found in fetal livers, 
however, mRNA for CYP3A7 has been detected in adults [16].  In addition, CYP3A7 
was not detected in the LS180 colon carcinoma cell line.  Even though the identity of the 
induced CYP3A isoform is not known, lines of evidence aforementioned suggest the 
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involvement of CYP3A4 primarily.  However, further studies are needed to identify the 
CYP3A isoform involved. 
As MRK-16 anti P-gp antibody recognizes the external epitope of P-gp, it was 
used in flow cytometry measurements to determine the surface expression of P-gp in 
LS174T cells, as the induced protein needs to be at the cellular surface to be functional.  
The fluoresence intensity of vehicle treated cells was compared with that of drug treated 
cells.  The fluoresence intensity in rifampin treated cells was 3.5 fold higher than vehicle 
treated cells, whereas reserpine induced P-gp expression about 4 fold over control cells 
(Figure 4.2).   
Vinblastine was used as a model substrate to measure P-gp function in LS174T 
cells.  Cellular accumulation of [3H]-vinblastine was measured in control and rifampin 
treated cells (Figure 4.3).  The accumulation of [3H]-vinblastine in rifampin treated cells 
was significantly less than in control cells as P-gp, an efflux transporter, decreased 
intracellular accumulation.  Cyclosporin A (a P-gp inhibitor) treatment significantly 
increased [3H]-vinblastine uptake in un-induced cells.  Though [3H]-vinblastine uptake 
was also increased by CsA in rifampin treated cells, this increase was not statistically 
significant.  In presence of an inhibitor, the uptake in control and treated cells should be 
comparable as the P-gp activity is being blocked / inhibited.  It is unclear why the results 
were not comparable in our study, but CsA is also a substrate for CYP3A. Since CYP3A 
was also induced in this cell line, an increase in CsA metabolism could have resulted in 
less CsA available for inhibition of P-gp.   
Geick et al. [27] demonstrated that human ABCB1 gene has a PXR response 
element in the 5’-upstream region.  These investigators reported the presence of PXR 
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mRNA in LS174T cells and measured the increased expression of ABCB1 mRNA after 
exposing the cells to various PXR activators and CYP3A inducers.  Recent studies by 
Synold et al. [24] further support the involvement of PXR in induction of ABCB1 
transcription.  To determine if PXR activators were able to induce the P-gp expression in 
LS174T cells, we treated these cells with a total of 18 compounds that had varying 
affinities for PXR.  A positive correlation was noted with a correlation coefficient of 0.53 
(Figure. 4.6) when compounds were rank ordered for PXR activation and induction of P-
gp).  On excluding outliers like hyperforin, troglitazone and taxol from the analysis, the 
correlation coefficient increased to 0.663.  Troglitazone and hyperforin showed increased 
affinity for PXR but did not increase (troglitazone) or moderately increased (hyperforin) 
P-gp expression.  The failure of troglitazone and moderate effect of hyperforin to increase 
P-gp expression may be explained based on the stability of these compounds. The PXR 
reporter gene assay was carried out for 24 hours whereas the LS174T cells were treated 
for 72 hours.  Because hyperforin and troglitazone are unstable in solution [105;106], this 
lag in assay measurement times may explain the lack of effect.   
Synold et al. [24] have reported a 50 fold activation of SXR by taxol in a reporter 
gene assay.  On the other hand Luo et al. [107] have demonstrated a 4 fold activation of 
PXR over control after taxol treatment. In our study, taxol activated PXR (2 fold) and 
induced P-gp expression (4 fold) over control.  The reason(s) for differential effect of 
taxol on P-gp expression as compared to PXR activation are unclear. Involvement of 
other orphan nuclear receptors apart from PXR or other pathways that could be 
responsible for induction of P-gp cannot be excluded.   
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In conclusion, our results demonstrate that P-gp and CYP3A proteins were 
induced in LS174T cells.  This cell line appears to be a good cell based model for 
screening compounds for their ability to induce both P-gp and CYP3A proteins.  We have 
shown that there was a correlation between the ability of compounds to activate PXR and 
to increase the expression of P-gp supporting the involvement of PXR in induction of the 
ABCB1 gene.   
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CHAPTER –V 
5. ADDITIONAL RESULTS  
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5.1. Sialic acid assay to determine the orientation or sidedness of 
membrane vesicles 
 In the case of inside-out vesicles, the cytoplasmic surface of the membrane forms 
the exterior side of the vesicles.  The quality of the inside-out vesicles can be determined 
by conducting assays to measure the accessibility of markers normally found on the outer 
surface of the cells.  Sialic acid is one such marker that is typically found on the outer 
surface of the cells [80].  In the case of inside-out vesicles, sialic acid will be present on 
the interior side of the vesicles and thus not accessible to enzymatic release.  Sialidase, 
which releases sialic acid from the surface, is not able to penetrate the inside-out vesicles 
and thus, only has access to sialic acid located on right side out vesicles and broken 
vesicles.  Detergents or surfactants can be used to disrupt the vesicles and expose the 
sialic acid from inside-out vesicles to sialidase.  Thus, experiments were carried out with 
and without Triton X-100 (detergent) to determine the percentage of inside-out vesicles.   
 A standard curve was generated with N-acetyl neuraminic acid (sialic acid) in 
concentrations ranging from 20 – 320 µg/ml.  The standards and samples were then 
derivatized as described in the experimental section (chapter 2) and measured using a UV 
spectrophotometer.  The standard curve was validated at low, medium and high 
concentrations with 6 replicates of each.  The % coefficient of variation (%C.V.) was less 
than 20% at all three concentrations.  On average, placental vesicle samples were found 
to consist of 18 - 20% inside-out vesicles, with the remainder being the right side out or 
broken vesicles.  Though the percent formation of inside-out vesicles was low, it was 
consistent from sample to sample.   
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5.2. Alkaline phosphatase assay to determine the enrichment of 
vesicles as well as the orientation of membrane vesicles 
Alkaline phosphatase is a marker enzyme localized in the microvillus membrane 
of cells and can be used to determine the enrichment of microvillus membrane when 
isolating membranes from cells or tissue homogenates [79].  Alkaline phosphatase 
catalyzes the formation of p-nitrophenol from p-nitrophenylphosphate [83].  The reaction 
is performed in alkaline pH as p-nitrophenol is colorless in acidic pH but forms a yellow 
color in alkaline pH, due to the p-nitrophenoxide ion.  This assay was used to measure the 
enrichment of the microvillus membrane in vesicle preparations as well as to determine 
the orientation of membrane vesicles.   
Alkaline phosphatase activity was determined in various fractions saved from the 
process of isolating membrane vesicles from placental tissue.  It was observed that the 
formation of p-nitrophenol was about 8.5 fold higher in the final microvillus membrane 
fraction as compared to the first homogenate.  Assuming the alkaline phosphatase activity 
in homogenate 1 as 100%, it was noted that supernatant 1 obtained from the 
centrifugation of homogenate 1 exhibited 92% of the original alkaline phosphatase 
activity, whereas, homogenate 2 exhibited only 8% of the original alkaline phosphatase 
activity.  These results suggest that most of the microvillus membrane vesicles were 
being isolated in first homogenate and there was no need for the second homogenization 
step, in agreement with results reported by Illsley et al. [79].   
 This assay was also used to determine the percentage of inside-out vesicles and 
therefore validate the results of the sialic acid assay.  The alkaline phosphatase assay was 
performed in the presence and absence of detergent and the percentage of inside-out 
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vesicles was calculated.  Results from this assay were in agreement with the results from 
sialic acid assay and showed that the percentage of inside-out membrane vesicles was 18-
20%.   
 
 
5.3. Uptake of radiolabeled substrate in membrane vesicles 
 As the substrates used in the uptake assay were observed to bind non-specifically 
to the filters, experiments were carried out to determine the best method for blocking the 
non-specific binding of substrate to the filters.  Based on literature evidence, 10% fetal 
bovine serum, 3% bovine serum albumin and high concentrations of unlabeled 
vinblastine were assessed for their ability to block the non-specific binding of vinblastine 
to the filters.  As seen in Table 5.1, the overall binding to glass fiber filters was less than 
to nitrocellulose filters.  In comparing different blocking media, 3% bovine serum 
albumin decreased the non-specific binding of radiolabeled vinblastine to less than 10% 
of the radioactivity added, irrespective of the type of filter.  Based on this experiment, 
nitrocellulose filters soaked in 3% bovine serum albumin were used for the uptake 
experiments.   
 To determine the optimum time for incubation of substrate with the vesicles, a 
time dependent uptake assay was carried out using vinblastine as the substrate.  The 
reactions were quenched at different time points in the presence and absence of ATP and 
uptake calculated.  As vinblastine is highly hydrophobic in nature, a plateau in rate of 
uptake was observed within 2 min and which remained constant for 15 min (Figure 5.1).  
A convenient time point of 10 min was therefore chosen for further studies.   
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 To determine if vinblastine uptake was mediated by P-gp without any interference 
from ABCP, vinblastine uptake was measured in the presence of P-gp and ABCP 
inhibitors.  Vinblastine uptake was inhibited by verapamil (10 and 100 µM), a P-gp 
inhibitor but not by FTC (10 µM), an ABCP inhibitor, suggesting that vinblastine uptake 
was mediated by P-gp and not by ABCP.  Similarly mitoxantrone uptake was measured 
in the presence of these same inhibitors.  Mitoxantrone uptake was inhibited 
approximately 65% by 10 µM FTC but less than 10% by 10 µM verapamil, suggesting 
that mitoxantrone uptake is primarily mediated by ABCP.  Thus, the P-gp mediated 
uptake of vinblastine was not confounded by effects of ABCP and likewise, the ABCP 
mediated uptake of mitoxantrone was not affected by concurrent mitoxantrone transport 
by P-gp.   
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Table 5-1  Non-specific binding of [3H]-vinblastine to nitrocellulose and glass fiber 
(GF/F) filters and effect of blocking solutions to reduce the non-specific binding 
 
Treatment             %  Radioactivity 
  Nitrocellulose GF/F filters 
10% FBS 42.8 8.3 
      
3% BSA 9.6 5.2 
      
5 µM cold VBL for 1 
hour 78.5 35.4 
      
5 µM VBL for 5 min 84.2 43.9 
      
1 µM VBL in quench 
buffer 76.5 22.8 
      
10 µM VBL in quench 
buffer 25.5 6.6 
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Figure 5-1  Time course of [3H]-vinblastine uptake in membrane vesicles 
Membrane vesicles were incubated with tritiated vinblastine in transport buffer at 37°C 
for various time intervals.  The open symbols represent uptake in the presence of 4mM 
ATP and the closed symbols in the absence of ATP.  Data represent means of duplicate 
determinations.   
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5.4. Induction studies in BeWo and JAR placental cells 
 P-gp from human intestinal cells is known to be induced by PXR ligands such as 
rifampin [16].  It has also been shown to be induced in human hepatocytes by some Ah 
receptor ligands like 3-methylcholanthrene [17].  With this background, we hypothesized 
that placental P-gp could also be induced by either PXR or Ah receptor ligands.  To 
determine the inducibility of placental P-gp, the placental choriocarcinoma cell lines JAR 
and BeWo were used as model systems for the human placenta.   
 After culturing the BeWo cells to 50% confluency, they were treated with 
increasing concentrations of rifampin and at the end of 72 h, the cells were lysed.  
Similarly, JAR cells were treated with rifampin and clotriamazole (PXR ligands) and 3-
MC and benzo-[a]-pyrene (Ah receptor ligands) at 50% confluency and at the end of 72 
h, the cells were lysed.  The cell lysates were analyzed for P-gp expression by 
immunoblotting as described in the experimental section (chapter 2).  Little expression of 
P-gp was detected in BeWo cells and expression was not induced by rifampin treatment.  
In the case of JAR cells, no P-gp expression was detected in either control or treated 
cells.   
 When the JAR cell lysates were probed for ABCP expression, high endogenous 
expression of ABCP was noted in control cells but expression did not increase after 
treatment with various xenobiotics (Figure 5.2 and 5.3).  A polyclonal, ABCP antibody, 
anti-MXR 87405 (gift from Dr. Susan Bates, NIH) was used as a primary antibody for 
the blot shown in Figure 5.2.  Use of this antibody resulted in substantial background 
signal and for unknown reasons did not recognize ABCP in human placental samples.  
When the BXP-21 antibody from Signet Laboratories was used as a primary antibody for 
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ABCP (Figure 5.3), we were able to detect ABCP in both human placental samples as 
well as in JAR placental cell lysates.  Since BXP-21 gave very little background signal 
and also was able to detect ABCP in human placental samples, this primary antibody was 
used for immunoblotting studies of ABCP in JAR cells and in human placental samples.  
However it was observed that the ABCP protein in human placental samples migrated 
differently than the ABCP in the JAR placental cell lysates.  These differences could be 
due to the differences in post-translational modifications, such as glycosylation.  A lower 
molecular weight band of ABCP was reported by Litman et al. [73] when a mitoxantrone 
selected colon carcinoma cell line which overexpresses ABCP, was treated with 
tunicamycin (inhibitor of N-glycosylation) and N-glycosidase F.  These results suggest 
that ABCP undergoes post-translational modifications at the N-linked glycosylation sites 
in this cell line.  Whether the ABCP protein in human placenta or the placental cell lines 
studied by us undergoes such glycosylation is not known.   
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Figure 5-2  Immunoblot of ABCP from JAR placental cell lysates probed with anti-
MXR antibody 87405 
97 kDa 
 
 
 
66 kDa 
 
 
 
 
45 kDa 
 
Lane 1 contains the molecular weight markers and lanes 2-7 are JAR cell lysates after 
treatment with various xenobiotics.  Lane 2: cells with no treatment, 3: acetone, 4: 
DMSO, 5: 3-Methylcholanthrene, 6 and 7: 50 µM and 10 µM Benzo-[a]-pyrene, 
respectively.   
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Figure 5-3  Immunoblot of ABCP from human placental samples and JAR placental 
cell lysates probed with BXP-21 primary antibody for ABCP 
Lanes 2-9 are human placental vesicle samples and lanes 10 and 11 are JAR cell lysates 
after DMSO and 10 µM rifampin treatment, respectively.  The ABCP protein in JAR cell 
lysates migrated higher than ABCP in human placental vesicles.   
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6. SUMMARY AND CONCLUSIONS 
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 The placenta is a vital link between mother and fetus and plays an important role 
in modulating the passage of xenobiotics from mother to fetus.  Generally, it is preferred 
that the fetus not be exposed to drugs ingested by the mother during pregnancy; however, 
in certain situations such as HIV-infection, fetal transfer of drugs is desired to achieve a 
positive therapeutic outcome.  Most HIV protease inhibitors are substrates for P-gp and 
thus potentially effluxed at the placental level back to the mother, decreasing their 
therapeutic efficacy in treating the fetus.  P-gp is known to be inducible by xenobiotics 
and thus, if placental P-gp induction occurred, a further decrease in the transfer of these 
drugs across the placenta would occur. Thus, understanding the inducibility of placental 
P-gp is important to be able to predict the therapeutic efficacy of drugs in treating fetal 
maladies and for dosage optimization.   
The placenta contains enzymes and transporters that can, respectively, metabolize 
xenobiotics or cause their efflux back to the mother.  Most placental metabolism research 
has been focused on the inducibility of placental oxidative enzymes in mothers who 
smoke during pregnancy.  Cigarette smoke contains polycyclic aromatic hydrocarbons 
(PAHs) which are metabolized to carcinogenic compounds by CYP1A1.  CYP1A1 is 
induced in response to cigarette smoking in human placenta.  P-gp, an efflux transporter, 
present in the placenta is also known to be induced by PAHs in hepatocytes, however, 
whether it is induced in placenta was heretofore unknown.  We report here the effect of 
smoking on expression and function of P-gp in the human placenta.  P-gp function was 
measured as the uptake of vinblastine in membrane vesicles prepared from human 
placenta.  To assure that vinblastine transport was being measured and not non-
productive binding, a series of initial uptake experiments were carried out in increasing 
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concentrations of sucrose.  Results of these experiments demonstrated that transport was 
intravesicular.  Additional experiments using the P-gp inhibitor verapamil demonstrated 
that the observed vinblastine transport was P-gp mediated.  Finally, it was noted that 
vinblastine transport was comparable between smokers and non-smokers.  Similarly no 
significant difference was observed in P-gp expression between the two groups.  
However, a substantial inter-individual difference was observed that was not attributable 
to the effects of smoking.  In view of the polymorphisms existing in the ABCB1 gene that 
can cause altered expression and function of P-gp, determination of P-gp genotype may 
be necessary to provide insight into the substantial inter-individual variation.   
 The effect of smoking on another efflux transporter, ABCP, was studied in human 
placenta.  This is the first report of ABCP functional studies in human tissue and its 
regulation by smoking.  Since ABCP is a half transporter, it is assumed to require 
dimerization to become a functional protein.  Immunblotting studies for ABCP were 
carried out with and without dithiothreitol (DTT), a reducing agent, to determine if 
ABCP existed as a dimer in non-reducing conditions.  A band was observed at 70 kDa in 
reducing conditions and at 140 kDa under non-reducing conditions.  These results 
suggest that ABCP exists as a dimer.  To further confirm the need for dimerization of 
ABCP for functionality, uptake studies in the presence and absence of DTT were carried 
out.  The ATP dependent uptake of mitoxantrone, an ABCP substrate, was decreased 
about 67% in the presence of DTT as compared to the absence of DTT.  This confirms 
that ABCP requires dimerization to become a functional protein.  When uptake of 
mitoxantrone was determined in the presence of ABCP and P-gp inhibitors, it was 
observed that mitoxantrone uptake was primarily carried out by ABCP, confirming that 
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mitoxantrone was a good substrate for measuring the function of ABCP in vesicles which 
also express P-gp.  No statistical difference was observed in either function or expression 
of ABCP between smokers and non-smokers.  Mutations have also been reported in 
ABCP overexpressing cell lines, however, whether these mutations exist in humans and 
can affect the level of expression and function of ABCP is not known yet.  Hence in 
addition to P-gp, genotyping studies for ABCP would also be beneficial in understanding 
inter-individual differences.   
 In agreement with literature evidence, placental CYP1A1 activity was induced in 
smokers as compared to non-smokers.  No correlation in activity was observed between 
CYP1A1 and P-gp in human placenta.  It has previously been established that the PAH 
benzo-[a]-pyrene, a substrate for CYP1A1, is also transported by P-gp.  Thus, based on 
our observations, it can be implied that the women who smoke during pregnancy and 
have high CYP1A1 activity but low P-gp activity, produce more toxic metabolites of 
PAH from the cigarette smoke and their fetuses probably have a higher risk of fetal 
exposure to these carcinogenic or mutagenic metabolites.  We now know that ABCP is 
functional in human placenta and probably also plays a protective role by preventing the 
placental transfer of xenobiotics.  It is not known whether PAHs are substrates for ABCP.  
ABCP was not affected by maternal smoking status in this study and the clinical 
significance of this finding is not known.   
 P-gp plays a role in the absorption, distribution and excretion of drugs.  It has 
broad substrate specificity and due to its efflux nature, leads to the decreased 
bioavailability of its substrates.  In addition, it is usually co-localized with CYP3A4, an 
important drug-metabolizing enzyme.  Furthermore, these two proteins have common 
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substrates and inducers.  Thus, both these proteins can act additively to decrease the 
therapeutic efficacy of common substrates and can lead to drug – drug interactions.  
Since P-gp and CYP3A4 are both expressed in intestine and have common substrates, we 
have evaluated LS174T cells, an intestinal cell line, as a model cell line to screen 
compounds for their ability to induce P-gp and CYP3A4 in hopes of better predicting 
drug – drug interactions.   
 Using rifampin as a model inducer, the induction of P-gp and CYP3A4 was 
studied in LS174T cells.  A dose and time dependent induction of P-gp expression was 
noted in these cells.  Using flow cytometry and MRK-16, a P-gp antibody that recognizes 
an external epitope of P-gp, increased surface expression of P-gp was detected in LS174T 
cells after rifampin treatment.  This suggests the presence of induced protein at the cell 
surface where its presence would be required for efflux of drugs out of the cells.  
Decreased vinblastine uptake after rifampin treatment as compared to control cells 
indicated induction of the functional activity of P-gp.  The studies herein report for the 
first time, induction of CYP3A activity in LS174T cells, though increased expression of 
CYP3A4 has been reported in LS180 cells.  A four fold induction of CYP3A activity, 
assessed by formation of 1’ - hydroxymidazolam after rifampin treatment, was noted as 
compared to control cells and this activity was inhibited more than 90% by 10 µM 
ketoconazole.  These results suggest that LS174T cells can be used as a model cell line to 
study the induction of P-gp and CYP3A.  The isoform of CYP3A induced in these cells, 
however, remains to be identified.   
 In addition, we have also compared and correlated the ability of compounds to 
induce P-gp in LS174T cells with their ability to activate PXR in a reporter gene assay.  
 111
The involvement of the nuclear hormone receptor, PXR, in induction of P-gp has been 
demonstrated; however, it may not be solely responsible for controlling P-gp expression.  
A positive correlation between the ability of compounds to induce P-gp in LS174T cells 
and activate PXR was observed, further supporting the role of PXR in P-gp induction.  
 In addition to being induced by PXR ligands, P-gp is also known to be induced by 
some Ah receptor ligands, however, this induction was not reported to proceed via the Ah 
receptor pathway.  To determine if placental P-gp is inducible by various xenobiotics, the 
placental choriocarcinoma cell lines, BeWo and JAR were used to study the induction of 
P-gp.  Placental cells were treated with the known inducers of P-gp, rifampin and 3-
methylcholanthrene.  P-gp expression was undetectable in JAR cells, in both control and 
treated cells, suggesting these compounds did not induce P-gp expression in this placental 
cell line.  Conversely low P-gp expression was detected in BeWo cells but no induction 
was observed after rifampin treatment.  Though induction at the protein level was not 
detected, it would be useful to perform mRNA studies to determine if induction at the 
gene level occurred.  Since PXR is known to be expressed in a tissue selective manner, 
determination of whether PXR is expressed in human placenta could also provide 
valuable insight into our lack of observed induction.   
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